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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acinetobacter baumannii 
 
Acinetobacter spp. are glucose-non fermentative gram-negative, strictly 
aerobic, non-motile, oxidasenegative, catalase-positive  coccobacilli that 
have been increasingly associated with severe infections [1,2].  
The existence of the genus Acinetobacter has been described  initially in 
1954, in one study [3],  followed by many changes that led in 1986 to 
the current classification system [4]. Based on more recent taxonomic 
data, it was proposed that members of the genus Acinetobacter should 
be classified in the new family Moraxellaceae. Using DNA-DNA 
hybridization technique have been described so far 32 differentiated 
species, of which 17 have been named [5-7]. (TABLE 1) Acinetobacter 
gen. sp 3 and 13TU are also pathogenic in human beings although they 
are less frequeltly encountered [8,9]. These three species are closely 
related genetically, and cannot be accurately differentiated by routine 
phenotypic methods; and it has been proposed that they should be 
grouped together into the so-called A. calcoaceticus-A. baumannii (Acb) 
complex [1]. 
A. baumannii is ubiquitous in nature and has been recovered from soil, 
water, animals, and humans. Acinetobacter species are normal 
inhabitants of human skin and are frequently isolated from the throat 
and respiratory tract of hospitalized patients. For this reason, it has 
been suggested that human skin could be the source of severe 
infections, such as bacteremia. However, this hypothesis has not been 
confirmed in healthy humans. [10] 
A. baumannii  has emerged in the last few decades as a major cause 
of healthcare-associated infections (HAIs) and nosocomial outbreaks 
[2]. 
 
 
 
 
 
 
Table 1 Classification of the genus Acinetobacter 
Species Source References  Species Source References  
Species that have valid name  
Acinetobacter calcoaceticus  Soil and humans (including clinical specimens)  
Acinetobacter baumannii  
Humans (including clinical specimens), soil, meat 
and Vegetables  
Acinetobacter haemolyticus  Humans (including clinical specimens)  
Acinetobacter junii  Humans (including clinical specimens)  
Acinetobacter johnsonti  
Humans (including clinical specimens) and 
animals  
Acinetobacter lwoffii 
(including gen.sp. 9)  
Humans (including clinical specimens) and 
animals  
Acinetobacter radioresistens  
Humans (including clinical specimens), soil and 
cotton  
Acinetobacter ursingii  Humans (including clinical specimens)  
Acinetobacter schindleri  Humans (including clinical specimens)  
Acinetobacter parvus  
Humans (including clinical specimens) and 
animals  
Acinetobacter baylyi  Activated sludge and soil  
Acinetobacter bouvetii  Activated sludge  
Acinetobacter towneri  Activated sludge  
Acinetobacter tandoii  Activated sludge  
Acinetobacter grimontii  Activated sludge  
Acinetobacter tjernbergiae  Activated sludge  
Acinetobacter gerneri  Activated sludge  
Species that have provisional designations  
Acinetobacter venetianus  Sea water  
Gen.sp. 3  
Humans (including clinical specimens), soil and 
vegetables  
Gen.sp. 6  Humans (including clinical specimens),  
Gen.sp. 10  
Humans (including clinical specimens), soil and 
vegetables  
Gen.sp. 11  
Humans (including clinical specimens), soil and 
animals  
Gen.sp. 13BJ or 14TU*  Humans (including clinical specimens)  
Gen.sp. 14BJ  Humans (including clinical specimens)  
Gen.sp. 15BJ  Humans (including clinical specimens)  
Gen.sp. 16  
Humans (including clinical specimens) and 
vegetables  
Gen.sp. 17  Humans (including clinical specimens) and soll  
Gen.sp. 13TU  Humans (including clinical specimens)  
Gen.sp. 15TU  Humans (including clinical specimens)  
Gen.sp. ‘between 1 and 3’  Humans (clinical specimens  
Gen.sp. ‘close to 13TU’  Humans (clinical specimens  
                                 Dijkshoorn et al., Nat Rev Microbiol 5: 939-951,2007 
 
Acinetobacter species identification 
 
DNA-DNA hybridization remains the reference standard for 
identification of Acinetobacter species, [4]. The phenotypic identification 
scheme proposed by Bouvet and Grimont in 1986 is based on 28 
phenotypic tests [4]. This identification scheme was refined in 1987 by 
the same authors and includes growth at 37°C, 41°C, and 44°C; 
production of acid from glucose; gelatin hydrolysis; and assimilation of 
14 different carbon sources [3]. In particular, the closely related and 
clinically most relevant species A. baumannii and Acinetobacter genomic 
species 13TU cannot be distinguished, while A. calcoaceticus and 
Acinetobacter genomic species 3 can only be separated by their growth 
properties at different temperatures [12]. Genotyping allows 
investigation of clonal spread and can be used to identify the source of 
the original infection. Traditional Acinetobacter strain typing methods 
include serotyping [13], multilocus enzyme electrophoresis [14] and 
DNA-based methods, including repetitive extragenic palindromic 
sequence-based PCR [15,16], amplified ribosomal DNA restriction 
analysis (ARDRA), pulsed-field gel electrophoresis (PFGE), amplified 
fragment length polymorphism (AFLP) [17]  and ribotyping [18,19,20]. 
However, these methods are not optimal: despite strenuous efforts at 
standardization, it is difficult to compare results obtained in different 
laboratories, and the methods are labor intensive and time consuming. 
Two other techniques have been proposed to characterize clinical 
isolates of A. baumannii, both based to amplification and sequence 
analysis. The first is the MultiLocus Sequence Typing (MLST), a 
technique that is a high-resolution molecular tool for discriminating 
between closely related bacterial species [21]. MLST data are 
reproducible and portable, facilitating comparison among laboratories 
worldwide. MLST is applicable to almost all bacterial species  
pathogenic,and allows to follow through comparison with a databases 
available on-line the global spread of strains with specific 
characteristics of virulence or antibiotic resistance [22]. The MLST 
provides an analysis of 7 housekeeping genes for A. baumannii and has 
a high discriminative power [7]. The second technique, i.e. sequence-
based typing (ST), allows the assignment of a particular strain of 
epidemic clones through  amplification and sequencing of three genes, 
in particular ompA (outer membrane protein A), csuE (part of a pilus 
assembly system, thought to be essential for biofilm formation and 
blaOXA-51-like  (intrinsic carbapenemase of A. baumannii). Only isolates 
belonging to epidemic clones have the same combination of alleles for 
the three genes [23]. 
 
 
Nosocomial infections 
 
The propensity for outbreaks of multidrug-resistant A. baumannii has 
been demonstrated clearly. Depending on the local circumstances, and 
the strain in question, the pattern of an outbreak can vary. To cause an 
epidemic bacteria must be able getting into the environment and this 
takes place mainly in three ways: by air, contamination of materials and 
through transmission by hospital staff. Multidrug-resistant (MDR) A. 
baumannii is a rapidly emerging pathogen in the healthcare setting, 
where it causes infections that include bacteremia, pneumonia, 
meningitis, urinary tract infection and wound infection. A.baumannii 
infects hospitalized, immunocompromised, long hospital-staying 
patients subjected to prolonged antibiotic therapy and invasive 
procedures. The main sites of infection are the respiratory tract, urinary 
tract, blood and skin. Infections often involve hospitalized patients in 
intensive care unit (ICU) and are associated with a high level of 
mortality. A scheme that depicts the dynamics of epidemic A. baumannii 
on a hospital ward is provided in FIG. 2 [1].An epidemic strain is most 
commonly introduced by a patient who is colonized. Once on a ward, 
the strain can then spread to other patients and their environment. The 
main characteristic of A. baumannii is the capability of surviving for 
prolonged periods in the environment, thus contributing to the 
transmission of the organism during outbreaks [24]. A. baumannii 
isolates are able to survive for weeks under dry conditions and have 
been detected on hospital bed rails until 9 days after the discharge of an 
infected patient, suggesting that hospital equipments could serve as a 
secondary reservoir for the infection [25]. During outbreaks A. 
baumannii has been recovered from various sites in the patients’ 
environment, including bed curtains, furniture and hospital equipment 
[26]. The bacteria can be spread through the air over short distances in 
water droplets and in scales of skin from patients who are colonized 
[27]. The transfer A. baumannii from hospital staff to patients appears 
to be an important means for spread of epidemics [2]. 
 
 
Figure 2 | Overview of the dynamics between patients, bacteria and the 
hospital environment. The possible modes of Acinetobacter baumannii entry 
into a ward are shown.  
• Entrance through a colonized patient is the most likely mode.  
• Introduction through contaminated materials [28]  
• Introduction by healthy carriers.  
The acquisition of A. baumannii by susceptible patients can occur through 
various routes, of which the hands of hospital staff are thought to be the most 
common, although the precise mode of transmission is usually difficult to 
assess. 
 
Dijkshoorn et al., Nat Rev Microbiol 5: 939-951,2007 
 
 
 
 
Pathogenicity and virulence factors 
 
In the past, Acinetobacter was considered to be an organism of low 
virulence. The occurrence of fulminant community’ acquired 
Acinetobacter pneumonia indicates that these organisms may 
sometimes be of high pathogenicity and cause invasive disease. Studies 
on Acinetobacter virulence factors are still at an elementary stage. A 
number of putative mechanisms that might have a role in colonization, 
infection and epidemic spread are summarized in FIG. 3 [1]. Genetic, 
molecular and experimental studies are required to elucidate these 
mechanisms in more detail. 
Recent DNA sequencing of a single A. baumannii strain identified 16 
genomic islands that carry putative virulence genes that are associated 
with, for example, cell-envelope biogenesis, antibiotic resistance, 
autoinducer production, pilus biogenesis and lipid metabolism [30]. 
Resistance to desiccation, disinfectants [29,31] and antibiotics is 
important for environmental survival. The extraordinary metabolic 
versatility of A. baumannii could contribute to its proliferation on a ward 
and in patients. Pilus-mediated biofilm formation on glass and plastics 
has been demonstrated [32]. If formed on medical devices, such as 
endotracheal tubes or intravascular catheters, these biofilms would 
probably provide a niche for the bacteria, from which they might 
colonize patients and give rise to respiratory-tract or bloodstream 
infections. Electron microscopy studies have demonstrated that pili on 
the surface of acinetobacters interact with human epithelial cells [33]. 
In addition, thread-like connections between these bacteria were 
suggestive of an early phase of biofilm formation. The pili and 
hydrophobic sugars in the O‑side-chain moiety of lipopolysaccharide 
(LPS) [34]  might promote adherence to host cells as a first step in the 
colonization of patients. In vitro and animal experiments have identified 
various factors that could have a role in A. baumannii infection. For 
example, A. baumannii outer membrane protein A (AbOmpA, previously 
called Omp38) has been associated with the induction of cytotoxicity 
[35]. Iron-acquisition mechanisms [36] and serum resistance [37] are 
attributes that enable the organism to survive in the bloodstream.  
 
Figure 3 The factors that contribute to Acinetobacter baumannii 
environmental persistence and host infection and colonization. Adherence to 
host cells, as demonstrated in an in vitro model using bronchial epithelial cells 
[33], is considered to be a first step in the colonization process. Survival and 
growth on host skin and mucosal surfaces require that the organisms can 
resist antibiotics and inhibitory agents and the conditions that are exerted by 
these surfaces. Outgrowth on mucosal surfaces and medical devices, such as 
intravascular catheters and endotracheal tubes [32], can result in biofilm 
formation, which enhances the risk of infection of the bloodstream and 
airways. Quorum sensing [30] might have a regulatory role in biofilm 
formation. Experimental studies have identified various factors that could 
have a role in A. baumannii infection, for example, lipopolysaccharide has been 
shown to elicit a proinflammatory response in animal models [38,39]. 
Furthermore, the A. baumannii outer membrane protein A has been 
demonstrated to cause cell death in vitro [35]. Iron-acquisition mechanisms 
[36] and resistance to the bactericidal activity of human serum [37] are 
considered to be important for survival in the blood during bloodstream 
infections. Environmental survival and growth require attributes such as 
resistance to desiccation [29,31] versatility in growth requirements [2], 
biofilmformingcapacity [32] and, probably, quorum-sensing activity [30]. 
Finally, adequate stressresponse mechanisms are thought to be required for 
adaptation to different conditions 
 
Dijkshoorn et al., Nat Rev Microbiol 5: 939-951,2007 
 
 
Antibiotic resistance in Acinetobacter baumannii  
 
Acinetobacter infections have become more difficult to treat owing to the 
emergence of isolates resistant to all commonly prescribed antimicrobial 
drugs [40]. The acquisition of resistance mechanisms by A. baumannii 
has been estimated as a recent phenomenon that started in the 1970s 
[41]. Resistance mechanisms involve antimicrobial-degrading enzymes, 
efflux pumps, target modification and porin deficiency [42]. The 
acquisition of a MDR phenotype can be caused by mobile genetic 
elements (plasmids, transposons and integrons) [43-47]. This extremely 
rapid development of antimicrobial resistance is due to the widespread 
use of antimicrobials in the hospital environment and to the ability of A. 
baumannii to respond rapidly to challenges issued by antimicrobials 
[48]. The Acinetobacter have become resistant to almost all antibiotics 
available, including aminoglycosides, quinolones and extended-
spectrum beta-lactam antibiotics. Most strains are resistant to 
cephalosporins, whereas resistance to carbapenems is increasingly 
reported frequently [49]. The percentages of resistance are generally 
higher for blocks of intensive care unit (ICU), particularly those 
epidemics [49,50].For pan-resistant isolates, colistin has been used with 
success in severe infections, including meningitis, bacteremia or 
pneumonia [51-53]. More recently, the use of colistin has been 
associated with lower rates of renal toxicity, suggesting that the 
incidence and severity of systemic toxicity owing to colistin 
administration was probably overstated [54-56]. 
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Journal of Clinical Microbiology, 47: 1281–1282 
The genus Acinetobacter currently contains up to 32 described named 
and unnamed (genomic) species [1]. Acinetobacter baumannii, genomic 
species 3, and 13TU, three of the most clinically relevant species, are 
genetically and phenotypically very similar to an environmental species, 
Acinetobacter calcoaceticus, and are therefore grouped together into the 
socalled A. calcoaceticus-A.baumannii (Acb) complex [1]. 
Because phenotypic identification of Acinetobacter isolates to the 
species level has proven to be insufficient, several genotypic methods 
have been developed for genomic species identification [1,57,59]. In the 
last 3 years, our laboratory has routinely used the 16S-23S rRNA gene 
intergenic spacer (ITS) sequence-based method described by Chang et 
al. [57] to delineate isolates belonging to the Acb complex to the 
genomic species level. We found the procedure accurate and easy to 
perform. However, we have recently encountered a discrepancy during 
the characterization of Acinetobacter strain 74510 isolated originally 
from a clinical source at the Prince of Wales Hospital, Hong Kong, in 
1995 [58]. Strain 74510 was previously identified as genomic species 
13TU by restriction analysis of amplified ribosomal DNA [58,59]. 
However, examination of the single PCR amplicon of the ITS region of 
strain 74510 (GenBank accession no. FJ360743) revealed an ITS 
sequence length of 607 bp, as opposed to the 615 bp reported by Chang 
et al. for the genomic species 13TU reference strain BCRC 15417 [57]. 
On the other hand, DNA sequence analysis of this 607-bp ITS of strain 
74510 showed an identity of 0.9561 to that of strain BCRC 15417 
(Table 1). Upon further analysis of nucleotide sequences in GenBank, 
the strain 74510 ITS sequence was also found to share increasing 
identity (0.9950 to 0.9967) with three other genomic species 13TU 
strains, namely, v104-2, 00574, and DR25612/96 (Table 1). 
Interestingly, the ITS length (607 bp) of these three genomic species 
13TU strains was also 607 bp, identical to that of strain 74510 (Table 
1). In addition, the ITS sequences of these genomic species 13TU strains 
74510, v104-2, 00574, and DR25612/96 appeared to be more closely 
related to the A. baumannii (genomic species 2) strain BCRC 10591T 
than to the 13TU reference strain BCRC 15417 (0.9538 to 0.9588 
versus 0.9171 identity) (Table 1), which reinforces the notion that 
genetic similarity among A. baumannii and genomic species 13TU is 
high [1] and perhaps suggests that BCRC 15417 may not be as 
representative for genomic species 13TU. 
Acinetobacter genomic species 13TU is the second most clinically 
relevant species in the Acb complex [1,60,61]. Therefore, we believe that 
it is important to extend the number of Acinetobacter genomic species 
13TU ITS sequences in the ITS sequence database for more-accurate 
genomic species identification. Also, we would suggest that the 
reference ITS sequence length for genomic species 13TU be 607 bp long 
and that strain 74510 could be considered as the “type” strain for 
genomic species 13TU. 
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Molecular epidemiology of carbapenem-resistant 
Acinetobacter baumannii strains in intensive care units 
of multiple Mediterranean hospitals 
 
Sir, 
Acinetobacter baumannii is an emerging opportunistic nosocomial 
pathogen in intensive care unit patients [62]. Outbreaks of  
carbapenem-resistant A. baumannii have been recently described in the 
Mediterranean [62-66]. The aim of the present study was to: (i) analyse 
the genetic relatedness of A. baumannii isolates associated with cross-
transmission episodes that occurred in 18 hospitals in Greece, Italy, 
Lebanon and Turkey from 1999 to 2006; and (ii) identify the 
carbapenemase genes and their flanking IS elements. Twenty-four A. 
baumannii strains were included in the study. Antimicrobial 
susceptibilities were determined by a reference microdilution method 
[67]. A. baumannii strains exhibiting imipenem and/or meropenem 
MIC_8 mg/L were considered carbapenem-resistant. PFGE and 
dendrogram analysis was performed as reported previously [65]. The 
majority of the strains were isolated with identical PFGE type from more 
than two patients of the same or different institutions. Strain 3237 of  
PFGE type C was typed from one patient in Beirut, Lebanon; strains of 
PFGE types M and M1 were typed from three patients each, in three 
and two different Turkish hospitals, respectively (Table 1). Thirteen 
major PFGE types were identified, PFGE types A and M showing two 
subtypes and one subtype, respectively [Table 1 and Figure S1, 
available as Supplementary data at JAC Online 
(http://jac.oxfordjournals.org/)]. Multiplex PCR experiments [23] 
assigned 15 isolates to previously defined sequence type (ST) groups 1, 
2 and 3, but were not able to identify the sequence group of 9 strains. 
Sequence-based typing was then performed using ompA, csuE and 
blaOXA-51-like sequences [23] These experiments confirmed the 
assignment of the strains of PFGE profiles A and B to ST group 1, 
strains of PFGE profiles D, E, G, H and I to ST group 2, and the strain 
of PFGE profile C to ST group 3. This is in accordance with previous 
reports showing that A. baumannii strains circulating in Europe 
belonged to ST groups 1 and 2 that corresponded to the previously 
characterized European clones II and I, respectively [62,23]. Strains of 
ST group 1 with PFGE profile A predominated, being isolated in two 
hospitals in Naples, Italy, and in three Greek hospitals from 2002 to 
2006, thus suggesting that the spread of this successful clone might 
have resulted from inter-hospital transfer of colonized patients within 
the same city or between different countries as described for other A. 
baumannii epidemics [62]. A. baumannii strains of six distinct PFGE 
types that were assigned to ST group 2 were isolated in Naples and 
Agrigento, Italy, in Thessaloniki, Athens and Serres, Greece, and in 
Beirut, Lebanon. Also, as already observed in northern Europe [62,23] a 
shift in the recent A. baumannii population towards ST group 1 
(European clone II) was observed in Greece and Italy. In addition, ST 
analysis identified two novel ompA alleles, 5 and 6 (GenBank accession 
numbers EU426837 and EU426838), four novel csuE alleles, 7, 8, 8-1 
and 9 (GenBank accession numbers EU426834– EU426836 and 
EU478794) and three novel blaOXA-51-like alleles, 6, 7 and 8 (GenBank 
accession numbers DQ149247, AJ309734 and EU375515) in isolates 
from Greece, Italy and Turkey. ompA allele 5 was 9 bp longer than other 
ompA alleles; csuE allele 8-1 differed from allele 8 reported by Turton et 
al. [23] by 1 nt. Two novel ST groups, 4 and 5, were assigned to strains 
showing allele profiles 4/7/4 and 5/8/7 or 5/8-1/7 at 
ompA/csuE/blaOXA-51-like loci, respectively. ST group 4 included strains 
of PFGE profile K isolated in Thessaloniki, Greece, and strains of PFGE 
profile L isolated in Kocaeli, Turkey. ST group 5 was assigned to several 
strains isolated in different Turkish cities. No novel ST group was 
assigned to strain 3866 of PFGE type F and strain 2977 of PFGE type N 
because they were micro-epidemic strains isolated from less than three 
patients. Interestingly, a peculiar distribution of A. baumannii strains of 
distinct ST groups was observed within the study countries. Thus, 
strains of ST groups 1 and 2, which were found all over Europe, [62,23] 
were frequently isolated in Greece, Italy and Lebanon. In contrast, 
strains of ST groups 4 and 5 were isolated within restricted 
geographical areas; strains of ST group 4 being isolated in Thessaloniki, 
Greece, and Kocaeli, Turkey, and strains of ST group 5 being isolated in 
several Turkish cities (Table1). Molecular epidemiology of carbapenem 
resistance genes showed that 21 of 24 strains were carbapenem-
resistant and produced OXA-58 carbapenemase, thus suggesting that 
the spread of blaOXA-58 might have contributed to their selection. Other 
carbapenemase genes that might have selected A. baumannii strains 
included blaOXA-23, found in strains of ST group 4 in Kocaeli, Turkey, as 
well as blaVIM-1 and blaVIM-4 metallo-b-lactamase genes, found in strains 
of ST groups 1 and 2, respectively, in Serres, Greece (Table 1).  
Additional epidemiological information was provided by the analysis of 
the IS elements surrounding blaOXA-58 [Table 1 and Figure S2, available 
as Supplementary data at JAC Online (http://jac.oxfordjournals.org/)].  
In particular, the 5' end was flanked by either ISAba2, IS18 or an 
ISAba1 element, while an ISAba3 element at the 3' end of the gene 
occurred in all strains. Of note, each of the IS elements flanking the 5' 
end of blaOXA-58 occurred in strains of distinct ST groups and PFGE 
profiles isolated in the same geographical area. Thus, the ISAba2 
element was detected in Greece and Italy, IS18 in Lebanon and Turkey 
and ISAba1 in Turkey and Italy, suggesting that they might have been 
acquired through horizontal gene transfer. In partial support of this 
hypothesis, plasmid-borne blaOXA-58 has been found in the majority of A. 
baumannii strains studied herein and in Acinetobacter spp. isolates in 
Europe [62,63–66,68]. Also, mobilization of IS elements by homologous 
recombination has been postulated,[68] and conjugative transfer of a 
plasmid-borne blaOXA-58 gene flanked by IS18 and ISAba3 elements at 
the 5' and 3' ends, respectively, has been demonstrated [66]. 
In conclusion, results indicate that Mediterranean A. baumannii 
epidemics were sustained by the spread of distinct genotypes belonging 
to ST groups 1, 2, 4 and 5. The blaOXA-58 gene flanked by IS elements 
was present in all carbapenem-resistant genotypes and possibly 
contributed to their selection. 
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Table 1. Molecular epidemiology of A. baumannii strains included in this 
study 
 
 
 
 
 
 
 
 
 
 
 
 Figure S1. Genotype analysis of digitized ApaI PFGE profiles of A. baumannii 
strains included in the study. A percentage genetic similarity scale is shown 
above the dendrogram. Isolate number, source, year of isolation, PFGE type 
and sequence group type are shown on the right-hand side of each profile.  
 
 
Figure S2. Schematic map of the genetic structures surrounding the blaOXA-58 
gene in A.baumannii strains. The horizontal black arrow indicates the blaOXA-58 
gene and the direction of transcription. IS elements are represented by empty 
rectangular boxes filled with black arrows indicating the transposase gene and 
the direction of transcription. ST and PFGE types of A. baumannii strains 
showing the corresponding structures are indicated. 
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ABSTRACT 
 
The molecular epidemiology of multidrug-resistant A. baumannii was 
investigated in two intensive care units of the V. Monaldi university 
hospital in Naples, Italy, from May 2006 to December 2007. Genotype 
analysis by pulsed-field gel electrophoresis (PFGE), tri-locus sequence-
based typing (3LST), and multi-locus sequence typing (MLST) of A. 
baumannii isolates from 71 patients identified two distinct genotypes 
classified as PFGE groups A and B in 14 and 57 patients, respectively. 
Of these, PFGE group A was assigned to 3LST group 1 and MLST-based 
ST2, and corresponded to European clone II identified in the same 
hospital during 2003-2004.  PFGE group B  was assigned to novel 3LST 
group 6 and ST78, and was isolated for the first time in May 2006 but 
became prevalent during 2007. The novel A. baumannii clone ST78/B 
was also isolated in five patients from two additional hospitals in Naples 
during 2007. The isolates of PFGE groups A and B were resistant to all 
antimicrobials tested including carbapenems, but were susceptible to 
colistin. Both isolates of PFGE groups A and B possessed a plasmid-
borne carbapenem-hydrolyzing oxacillinase gene blaOXA-58 flanked by 
ISAba2 and ISAba3 elements at the 5’ and 3’ ends, respectively. The 
selection of the novel A. baumannii epidemic clone ST78/B might have 
been favored by the acquisition of the blaOXA-58 gene. 
 
 
 
 
 
 
INTRODUCTION 
 
Acinetobacter baumannii is an emerging opportunistic nosocomial 
pathogen, with increasing prevalence worldwide, responsible for a 
variety of nosocomial infections, especially in intensive-care-unit (ICU) 
patients [1,62]. Several hospital outbreaks caused by the selection of 
multiresistant A. baumannii clones have been described in Europe and 
worldwide [81,1,62,75]. Genotypic characterization of epidemic A. 
baumannii isolates through amplified fragment length polymorphism 
analysis has identified clusters of highly similar strains, which were 
assumed to represent distinct clonal lineages and were defined as 
European clones I, II and III [50,74]. Similarly, three distinct groups 
were recently identified among A. baumannii isolates from five different 
countries by sequence-based typing (ST),  group 1 corresponding to 
European clone II, group 2 to European clone I, and group 3 to 
European clone III [23]. Moreover, epidemics caused by A. baumannii 
genotypes assigned to novel ST groups 4 and 5 have been recently 
described in different Greek and Turkish cities [99]. The majority of the 
outbreaks occurred in Europe were caused by carbapenem-resistant 
strains that carried the blaOXA-58 gene or a distinct CHDL gene  
[70,57,67,96,99,90,72,68,2,75,66]. We have previously reported the 
occurrence of two sequential outbreaks from August 1999 to February 
2001 and from January 2002 to December 2002 along with the 
emergence of carbapenem resistant A. baumannii in the ICU of Federico 
II University hospitals in Naples, Italy, during 2002 [78]. More recently, 
we have shown that the same epidemic A. baumannii clone isolated 
during 2002 was responsible for a large and sustained outbreak in the 
V. Monaldi tertiary-care teaching hospital of Naples between June 2003 
and June 2004 [65]. An increase in the number of cases of A. 
baumannii was observed after two years in the V. Monaldi hospital. The 
objectives of the present study were: (i) to investigate the molecular 
epidemiology of A. baumannii in the V. Monaldi hospital, (ii) to study the 
genetic characteristics of A. baumannii isolates responsible for the 
epidemic, (iii) to analyse the antimicrobial susceptibility of the A. 
baumannii isolates and their mechanisms of resistance. 
 
MATERIALS AND METHODS 
 
 
SETTING AND STUDY PERIOD.  
The V. Monaldi Hospital is a 600-bed tertiary-care teaching hospital 
serving approximately 20,000 admissions per year. The hospital is 
provided with five intensive care units (ICUs): a neonatal ICU, a 
coronary ICU, and a cardiac surgery ICU, a general and specialist 
surgery ICU (namely post-operative ICU, PO-ICU) and a cardio-
respiratory ICU (CR-ICU). PO-ICU and CR-ICU are located in a recently 
renovated area of the hospital, are connected by a short internal 
corridor and each has eight beds and an isolation box. Although 
spatially very close, the two wards have distinct staffs and medical 
equipments. Patients admitted to PO-ICU are inpatients undergoing 
major elective surgery, while CR-ICU admits both inpatients requiring 
intensive care and outpatients from other city or region ICUs. The 
present study analyzed 71 A. baumannii isolates from 71 patients in 
CR-ICU and PO-ICU wards between May 2006 and December 2007.  
 
MICROBIOLOGICAL SURVEILLANCE AND EPIDEMIOLOGICAL DATA.  
Patient microbiological screening at admission to CR-ICU and PO-ICU is 
routinely performed; further specimens are collected during patients’ 
stay upon clinical judgement. Moreover, starting from January 2007 
monthly reporting to the local infection control team of all 
microbiological isolations in high risk areas was implemented. Analysis 
of data for the first part of the study period (May 2006-December 2006) 
was performed retrospectively. Epidemiological data for the 76 A. 
baumannii-positive patients in V. Monaldi, Cotugno and A. Cardarelli 
hospitals (age, gender, primary diagnosis, infectious comorbidities, and 
outcome) were retrospectively collected from hospital discharge cards. 
A. baumannii-associated mortality was defined as death occurring 
during A. baumannii infection. Microbiological data were analyzed using 
SPSS v. 11.0 (SPSS Inc., Chicago, IL, USA) by means of Student’s t test 
or Pearson’s Chi-squared test as appropriate. Results were considered 
to be statistically significant at p<0.05.  
 
BACTERIAL STRAINS AND MICROBIOLOGICAL METHODS.  
A. baumannii isolates were obtained from clinical specimens by 
standard methods, followed by isolation in pure culture on MacConkey 
agar plates, and were stored at -80°C in nutrient broth containing 
glycerol 20% v⁄v. Strains were originally identified as Acinetobacter 
baumannii-A. calcoaceticus complex by using the Vitek 2 automatic 
system with ID-GNB card for identification of gram-negative bacilli 
(bioMerieux, Marcy-l’Etoile, France). A. baumannii species identification 
was confirmed by amplification of blaOXA-51-like gene and PCR 
amplification and sequence analysis of the 16S-23S rRNA intergenic 
spacer region [57, 23]. 
 
ANTIMICROBIAL SUSCEPTIBILITIES.  
MICs were determined by a microdilution method  according to Clinical 
and Laboratory Standards Institute document M7-A6 [67]. Breakpoint 
values were those recommended from the CLSI [67]. Breakpoints for 
colistin were those from the British  Society for Antimicrobial 
Chemotherapy (BSAC) [71]. Etest MBL strips (AB BIODISK, Solna, 
Sweden) were used to evaluate the presence of metallo-beta-lactamase 
(MBL) activity according to manufacturer’s procedure. The role of 
oxacillinase production in carbapenem resistance was assessed by 
determining carbapenem MICs by microdilution in the presence and 
absence of 200 mM NaCl, as described previously [66]. 
 
 PULSED-FIELD GEL ELECTROPHORESIS (PFGE)  
AND DENDROGRAM ANALYSIS. 
 
ApaI DNA macrorestriction, PFGE and dendrogram analysis of A. 
baumannii isolates were performed as previously reported. 
Interpretation of genomic relatedness was performed using Tenover’s 
criteria [73]. 
 
 
IDENTIFICATION OF PCR-BASED SEQUENCE GROUPS AND 
SEQUENCE-BASED TYPING (ST). 
Multiplex PCRs and sequence-based typing were performed as 
previously described [23]. Assignment of novel alleles and ST types was 
performed using the bioinformatic tools at the Health Protection Agency 
web site on A. baumannii sequence typing that has been developed and 
maintained by Drs. J.F. Turton and R. Meyers 
(http://www.hpabioinformatics.org.uk/AB/home.php). 
 
MULTILOCUS SEQUENCE TYPING (MLST).  
MLST analysis was performed using the Institut Pasteur’s MLST 
scheme, publicly available from the MLST web site at 
http://www.pasteur.fr/mlst. This MLST scheme is based on sequencing 
of an internal portion of the seven genes 60-kDa chaperonin (CPN60), 
protein elongation factor EF-G (fusA), citrate synthase (GLTA), CTP 
synthase (pyrG), homologous recombination factor (RECA), 50S 
ribosomal protein L2 (rpIB) and RNA polymerase subunit B (rpoB). 
Primer pairs for three of these genes (cpn60, gltA and recA) were 
previously designed by Bartual and al. [7]. Primer pairs for three other 
genes (fusA, pyrG and rplB) are derived from primers initially proposed 
by Santos and Ochman [119]. Finally, primers for gene rpoB were 
designed previously [120]. PCR conditions were 35 cycles (denaturation 
at 94°C for 1 min, annealing at 58°C for 1 min, and extension at 72°C 
for 1 min) preceded by a 3-min denaturation at 94°C and followed by a 
5-min extension at 72°C. Further details on this MLST scheme can be 
found at www.pasteur.fr/mlst. 
PCR ANALYSIS OF CARBAPENEMASE GENES AND IS SEQUENCES.  
PCR analysis for carbapenemase-encoding genes in Acinetobacter spp. 
(blaIMP, blaVIM, blaSIM, blaOXA-23-like, blaOXA-24-like, blaOXA-51-like, blaOXA-58) was 
performed as previously described [66]. PCR characterization of the 
blaOXA-58-surrounding IS was performed as described [68]. The 
colinearity between IS elements and blaOXA-66 or blaOXA-90 gene was 
analyzed using primers for IS elements described previously by Poirel 
and Nordmann [68] and for the blaOXA-51-like gene described 
previously by Turton et al. [79]. 
 
PLASMID ANALYSIS.  
Plasmid DNA preparations were performed by using the QIAfilter 
Plasmid purification Maxi kit adapted for low-copy number plasmids 
(QIAGEN Corporation, Milan, Italy) according to manufacturer’s 
procedure. HindIII-generated fragments were separated on 1% agarose 
gels, transferred onto nylon membranes, and hybridized with PCR-
generated probes specific for blaOXA-58. 
 
MATING EXPERIMENTS   
Filter mating was performed using A. baumannii isolates of PFGE type A 
or B, resistant to imipenem and susceptible to rifampicin, and 
Acinetobacter genomic species 3 strain 4442 [115], susceptible to 
imipenem while resistant to rifampin, as donor and recipient cells, 
respectively. Transconjugants were selected on BHI agar plates 
containing imipenem (16 mg/L) + rifampin (100 mg/L). The frequency of 
transfer was calculated as the number of transconjugants divided by 
the number of surviving recipients.  
 
DNA SEQUENCING AND COMPUTER ANALYSIS OF SEQUENCING 
DATA 
DNA sequences of plasmid pABNA1 and pABNA2 were amplified using 
primers 5'-GTCACGCCAGTATTAACCAA-3' and 5'-
TCGTTTACCCCAAACATAAGC-3', spanning plasmid oriV and ISAba3, 
respectively. DNA sequences of PCR products was performed using the 
ABI Prism BigDye Terminator v3.1 ready reaction cycle sequencing kit 
and the 3730 DNA Analyzer (Applied Biosystems, Foster City, CA, USA). 
DNA sequences were assembled using the program Autoassembler 
version 1.4 (Applied Biosystems, Foster City, CA, USA) and annotated 
using the BLAST program [112] and the sequence annotation tools 
integrated into the Sequin program version 7.9 available at 
http://www.ncbi.nlm.nih.gov/Sequin/index.html. 
NUCLEOTIDE SEQUENCE ACCESSION NUMBERS.  
The nucleotide sequences of the novel alleles identified for A. baumannii 
isolates of ST group 6 have been deposited in the GenBank nucleotide 
database under accession numbers EU433384 (ompA allele 7), 
EU433383 (csuE allele 10) and EU433382 (blaOXA-51like allele 9 
corresponding to blaOXA-90), respectively. The nucleotide plasmid 
sequences pABNA1and pABNA2, amplified from isolates 3979 (PFGE 
type A) and 3957 (PFGE type B) have been assigned accession numbers 
GQ338082 and GQ338083, respectively, in the Genbank nucleotide 
database. Allele sequences of ST78 are available from the A. baumannii 
MLST web site at www.pasteur.fr/mlst. 
 
RESULTS 
 
Molecular epidemiology of A. baumannii in the hospital.  
We have recently described an A. baumannii outbreak between 
June 2003 and June 2004 in the V. Monaldi hospital of Naples, Italy 
[65]. During the two subsequent years, only few sporadic A. baumannii 
cases were detected in the hospital. The epidemiology of A. baumannii 
was studied in CR-ICU and PO-ICU of the hospital between May 2006 
and December 2007, when a further increase of the number of A. 
baumannii isolates was observed in the two wards, while no isolates 
were obtained from other wards. During the study period, a total of 
1760 patients were admitted to the two wards (514 and 1240 to CR-ICU 
and PO-ICU, respectively). A. baumannii was isolated from 101 patients, 
with an overall A. baumannii isolation rate of 5.7% (14.6% and 2.1% for 
CR-ICU and PO-ICU, respectively, p<.05). A. baumannii was isolated in 
75 CR-ICU patients who showed a mean number of positive specimens 
of 2.17±1.58. In PO-ICU 26 patients proved to be positive for A. 
baumannii, with a mean number of positive specimens of 2.08±1.35 
(p>.05). Mean length of stay in the two wards was calculated and proved 
to be of 10.98±22.32 and 2.22±2.94 days for CR-ICU and PO-ICU, 
respectively (p<.05). 
To investigate whether the increase in the frequency of isolation of A. 
baumannii during the study period was caused by the spread of 
epidemic clones, 71 available, non-repetitive A. baumannii isolates from 
71 patients between May 2006 and December 2007 were genotyped: 54 
were from CR-ICU patients (73.3% of patients) and 17 from PO-ICU 
(61.5% of patients). One Acinetobacter isolate was not included in the 
study because species identification as A. baumannii was not confirmed 
by molecular methods. Molecular typing by PFGE identified two major 
PFGE groups, that differed in the migration of more than six bands, in 
14 and 57 isolates, which we named A and B, respectively. Of the 14 
isolates of PFGE group A, twelve showed an identical macrorestriction 
pattern (type A) whereas two showed two- to three-fragment variations 
and were classified into types A1 and A2, respectively. Fifty-six isolates 
of PFGE group B showed an identical macrorestriction pattern (type B) 
whereas one showed a two-fragment variation and was designated as 
type B1, respectively (Figure 1A and TABLE S1). The epidemic PFGE 
profile A was identical to that of the epidemic A. baumannii strain 2638 
isolated in the V. Monaldi hospital during 2004 [65] (Figure 1A). The 
lower respiratory tract was the most frequent site of isolation (9 of 14 
and 45 of 57, for PFGE groups A and B, respectively) (p>.05) and was 
associated with clinical infection as primary diagnosis or infectious 
comorbidity in 3 of 10 and 11 of 44 patients for PFGE groups A and B, 
respectively. Nine A. baumannii isolates from blood were assigned to 
PFGE type B, one to PFGE type A (p>.05), and were always associated 
with clinical infection. PFGE group B was also isolated from 1 wound 
swab,  the urinary tract of one patient and one catheter tip, while PFGE 
group A was also isolated from the upper respiratory tract of 1 patient, 
the central venous catheter and the catheter tip of 2 and 1 patients, 
respectively. Crude mortality and A. baumannii-associated mortality 
was 64% (9/14) and 21% (3/14), respectively, for patients with isolation 
of A. baumannii of PFGE group A, 75% (43/57) and 25% (14/57), 
respectively, for patients with isolation of A. baumannii of PFGE group B 
(TABLE S1). Genotype analysis using the multiplex PCRs and tri-locus 
sequence-based typing approach described by Turton et al [23] assigned 
all 14 isolates of PFGE group A to previously defined three-locus 
sequence type (3LST) group 1 (Figure 1B and TABLE S1). The multiplex 
PCR approach identified a distinct PCR pattern in the other 57 isolates 
of PFGE group B with the amplification of blaOXA-51-like and ompA but not 
csuE alleles in the PCR mix 1 and amplification of csuE but not blaOXA-
51-like and ompA alleles in the PCR mix 2 (Figure 1B). Tri-locus sequence-
based typing identified an identical allele profile 7/10/9 at 
ompA/csuE/blaOXA-51-like loci in the 57 isolates of PFGE group B that 
were assigned to a novel 3LST group 6 (TABLE S1). The differences in 
group-specific PCRs patterns facilitated rapid identification of the A. 
baumannii isolates belonging to different ST groups 1 and 6 into the 
hospital and were used as preliminary typing approach of the isolates. 
MLST based on the conserved regions of cpn60, fusA, gltA, pyrG, recA, 
rplB, rpoB housekeeping genes identified ST2 for isolates of PFGE group 
A, allelic profile 25/3/6/2/28/1/29, which corresponds to a novel ST 
assigned as  ST78 for isolates of PFGE group B, respectively (TABLE 
S1). 
Molecular epidemiology of A. baumannii isolates showed that the 
outbreak in the two wards of the V. Monaldi hospital was caused by the 
spread of two distinct epidemic clones, that were isolated in two 
consecutive temporal clusters, one clone prevailing over the other. In 
fact, clone ST2/A was identified in 10 CR-ICU patients and in 4 PO-ICU 
patients, while clone ST78/B was found in 44 CR-ICU patients and in 
13 PO-ICU patients. Moreover, ST2/A isolates occurred between May 
2006 and February 2007 in both wards, while ST78/B isolates were 
first identified in CR-ICU ward in May 2006 and predominated in both 
wards since March 2007 (Figure 2). Five additional MDR A. baumannii 
strains of ST78/B profile were isolated in ICU wards of the Cotugno and 
A. Cardarelli hospitals in Naples (4 and 1 isolates, respectively) during 
2007 (TABLE S1).  
 
 
 
  
Fig. 1. (A) ApaI PFGE profiles of representative A. baumannii strains included 
in the study. Capital letters on the top of the lanes indicate PFGE types 
identified; m, phage lambda DNA molecular mass markers. Isolate number is 
shown on the bottom of each lane. Sizes of lambda DNA molecular mass 
markers are shown on the right-hand side of the panel. (B) Multiplex PCR to 
selectively amplify ompA, csuE and blaoxa-51-like alleles. ST groups identified are 
indicated on the top of the lanes; m, 1 kb DNA ladder molecular mass markers 
(Promega, Milan, Italy). Isolate number is shown on the bottom of each lane. 
 
 
 
 
Fig. 2.  Molecular epidemiology of A. baumannii in the V. Monaldi hospital, 
Naples, Italy, during 2006–2007. Grey and white bars represent isolates of 
PFGE group A from cardio-respiratory-ICU (CR-ICU) and post-operative-ICU 
(PO-ICU), respectively; black and dotted bars represent isolates of PFGE group 
B from CR-ICU and PO-ICU, respectively. 
 
 
 
Antimicrobial susceptibility patterns of A. baumannii isolates.  
Both A. baumannii isolates of PFGE groups A and B from the V. Monaldi 
hospital showed a multi-drug resistant antibiotype. In particular, they 
were resistant to ampicillin–sulbactam, piperacillin–tazobactam, broad-
spectrum cephalosporins, fluoroquinolones and aminoglycosides, 
intermediate or resistant to imipenem and rifampicin, intermediate to 
meropenem,  but were susceptible to colistin sulphate. Interestingly, 5 
isolates of PFGE group A showed high-level resistance to rifampicin 
(TABLE 1 and TABLE S1). All four A. baumannii isolates of PFGE type B 
from the Cotugno hospital in Naples showed antimicrobial susceptibility 
profile identical to isolates of PFGE type B from the V. Monaldi hospital; 
the single A. baumannii isolate of PFGE type B from the A. Cardarelli 
hospital was susceptible to imipenem (MIC 1.0 mg/liter) and 
meropenem (MIC 0.5 mg/liter) (TABLE S1). Tests with Etest MBL strips 
showed that all carbapenem-resistant isolates of PFGE groups A and B 
were intermediate or resistant to imipenem (MICs 8–16 mg⁄liter), but 
were negative for MBL production (imipenem-EDTA MICs, 4–8 mg⁄liter). 
To study the contribution of oxacillinases to imipenem resistance, 
imipenem MICs were analyzed in the presence of 200 mM NaCl for 
carbapenem-resistant isolates of PFGE groups A and B through a 
microdilution method. These experiments showed that imipenem MICs 
(16 mg/liter) were inhibited by up to eightfold in the presence of NaCl (2 
mg/liter).  
 
 
 
 
 
 
TABLE S1.  Epidemiological, phenotypic and genotypic features of A. baumannii strains included in the study 
Strain Culture date Ward 
Age/  
gender 
Primary 
diagnosis 
Infectious 
comorbidity 
Outcome 
Isolate  
source 
PFGE   
Tri-locus 
ST  
MLST   Antibiotic MIC 
                Type Group ST IPM MEM SAM AK GM RIF COL 
                                Monaldi Hospital 
3978 15/05/2006 CR-ICU 61/M 
Respiratory 
failure 
Pneumonia Exitus BA B 6 78 32 16 125 125 32 4 <=0,5 
3979 29/05/2006 CR-ICU 85/F 
Respiratory 
failure 
Pneumonia 
Voluntary 
discharge 
BA A 1 2 32 8 32 125 8 4 <=0,5 
3980 05/06/2006 CR-ICU 67/F 
Respiratory 
failure 
Pneumonia* Exitus BA B 6 78 16 8 125 125 32 4 <=0,5 
3982 09/06/2006 PO-ICU 81/F 
Acute 
myocardial 
infarction 
 
Exitus BA A 1 2 16 16 32 125 8 2 <=0,5 
3993 19/06/2006 CR-ICU 83/F Pneumonia   Exitus BA A1 1 2 16 4 32 125 8 2 <=0,5 
3983 28/06/2006 CR-ICU 67/M Lung cancer Sepsis Exitus BC A 1 2 16 4 125 4 8 >500 <=0,5 
3991 17/07/2006 CR-ICU 79/F Pneumonia*   Transferred PS A 1 2 16 4 32 4 8 4 <=0,5 
3994 17/07/2006 CR-ICU 75/M 
Aortic 
dissection 
  Exitus BA B 6 78 8 4 125 125 32 2 <=0,5 
3984 17/07/2006 CR-ICU 81/F 
Respiratory 
failure 
  Discharge BA A 1 2 16 8 32 32 8 4 <=0,5 
4137 31/07/2006 CR-ICU 67/F 
Respiratory 
failure 
Pneumonia Exitus BA A 1 2 8 4 125 125 256 >500 <=0,5 
3987 03/08/2006 CR-ICU 47/F 
Respiratory 
failure 
Pneumonia Exitus BA B 6 78 16 4 64 125 32 4 <=0,5 
3985 14/08/2006 CR-ICU 67/M Pneumonia   Exitus BA B 6 78 16 16 125 16 4 2 1 
3992 21/08/2006 CR-ICU 50/F 
Respiratory 
failure 
  Exitus BA A 1 2 32 8 32 125 8 4 <=0,5 
3990 23/08/2006 CR-ICU 76/M Pneumonia   Transferred CVC A 1 2 32 16 64 16 4 >500 <=0,5 
3989 28/08/2006 CR-ICU 59/M 
Esophageal 
cancer 
Pneumonia* Exitus BA B 6 78 16 8 125 125 256 2 1 
4138 12/09/2006 PO-ICU 68/M Lung cancer   Exitus BA A 1 2 8 8 32 16 4 >500 <=0,5 
3986 06/11/2006 CR-ICU 19/M 
Respiratory 
failure 
  Exitus CT A2 1 2 16 4 32 >250 8 4 <=0,5 
3988 06/11/2006 CR-ICU 76/F 
Respiratory 
failure 
  Discharge BA A 1 2 32 4 32 125 8 4 <=0,5 
3956 05/01/2007 PO-ICU 26/M 
Respiratory 
failure 
Sepsis Exitus BC B 6 78 32 8 64 125 32 4 <=0,5 
4155 08/01/2007 PO-ICU 81/M 
Abdominal 
aortic 
aneurysm 
Vascular 
prosthesis 
infection* 
Exitus BA A 1 2 16 16 125 16 64 >500 <=0,5 
4156 08/01/2007 PO-ICU 68/M 
Larynx 
cancer  
  Discharge BA B 6 78 8 8 125 >250 8 6 <=0,5 
3958 15/01/2007 CR-ICU 81/M 
Respiratory 
failure 
  Exitus BA B 6 78 32 8 125 32 32 16 <=0,5 
4157 15/01/2007 PO-ICU 66/M 
Colorectal 
cancer 
  
Voluntary 
discharge 
BA B 6 78 16 8 125 >250 32 4 <=0,5 
3957 18/01/2007 PO-ICU 44/M 
Bronchiectas
is 
Lung abscess Discharge BA B 6 78 16 8 125 32 32 4 <=0,5 
3942 24/01/2007 PO-ICU 81/F 
Respiratory 
failure 
  
Voluntary 
discharge 
BA B 6 78 16 8 125 125 32 16 <=0,5 
3997 29/01/2007 CR-ICU 85/F 
Respiratory 
failure 
  Exitus BA B 6 78 16 8 64 16 32 2 <=0,5 
4158 03/02/2007 PO-ICU 56/M Lung cancer   Exitus CVC A 1 2 16 16 64 >250 8 >500 <=0,5 
3944 12/02/2007 PO-ICU 65/F 
Intestinal 
occlusion 
  Exitus BA B 6 78 16 8 125 >250 32 4 <=0,5 
3945 16/02/2007 PO-ICU 39/M 
Aortic 
dissection 
  Transferred BA B 6 78 8 8 64 32 64 4 <=0,5 
3960 23/02/2007 CR-ICU 45/M 
Pneumocysto
sis* 
Sepsis Exitus BC B 6 78 16 8 125 32 32 2 <=0,5 
3998 03/03/2007 CR-ICU 52/F 
Respiratory 
failure 
Sepsis  Exitus BC B 6 78 16 8 125 >250 32 4 <=0,5 
3946 13/03/2007 PO-ICU 75/M 
Not specified     
hemorrhage 
  Exitus WS B 6 78 8 8 125 >250 32 4 <=0,5 
3999 19/03/2007 CR-ICU 66/F Mediastinitis   Exitus BA B 6 78 8 4 64 125 32 4 <=0,5 
3961 21/03/2007 CR-ICU 77/M 
Aortic 
dissection 
  Exitus BA B 6 78 8 8 125 125 64 2 <=0,5 
4000 21/03/2007 CR-ICU 62/M 
Respiratory 
failure 
  Exitus BA B 6 78 16 16 125 125 32 4 <=0,5 
3962 10/04/2007 CR-ICU 71/F 
Respiratory 
failure 
  Exitus BA B 6 78 32 4 125 32 32 2 <=0,5 
4001 30/04/2007 CR-ICU 78/M 
Respiratory 
failure 
  Discharge BA B 6 78 32 8 125 125 32 4 <=0,5 
4002 30/04/2007 CR-ICU 75/F Pneumonia   Exitus BA B 6 78 8 4 125 32 64 4 <=0,5 
3963 04/05/2007 CR-ICU 76/F 
Respiratory 
failure 
  Exitus BA B 6 78 16 4 125 32 32 4 <=0,5 
3947 08/05/2007 PO-ICU 75/M 
Bladder 
cancer 
  Discharge UC B 6 78 16 4 125 125 32 4 <=0,5 
4139 14/05/2007 CR-ICU 57/F 
Respiratory 
failure 
  Exitus CT B 6 78 16 8 64 125 32 4 <=0,5 
3948 26/05/2007 PO-ICU 64/M 
Colorectal 
cancer 
Sepsis Exitus BC B 6 78 8 8 125 125 32 4 <=0,5 
3969 04/06/2007 CR-ICU 74/M 
Wegener's   
granulomato
sis 
  Exitus BA B 6 78 8 8 64 16 32 4 <=0,5 
4140 05/06/2007 CR-ICU 79/F 
Respiratory 
failure 
  Exitus BA B 6 78 8 8 125 125 32 4 <=0,5 
3970 19/06/2007 CR-ICU 52/F 
Acute 
myocardial 
infarction 
Pneumonia Exitus BA B 6 78 16 8 64 16 64 4 <=0,5 
4141 21/06/2007 CR-ICU 49/M 
Respiratory 
failure 
  Transferred BA B 6 78 16 4 64 16 32 4 <=0,5 
3971 25/06/2007 CR-ICU 68/F 
Aortic 
dissection 
Sepsis 
Voluntary 
discharge 
BC B 6 78 32 8 125 125 64 4 <=0,5 
4142 28/06/2007 CR-ICU 76/M 
Respiratory 
failure 
  Exitus BA B 6 78 8 4 125 16 32 4 <=0,5 
4143 02/07/2007 CR-ICU 54/M 
Amyotrophic 
lateral 
sclerosis 
Pneumonia Discharge BA B 6 78 8 8 125 125 32 4 <=0,5 
3972 16/07/2007 CR-ICU 85/M 
Respiratory 
failure 
 Pneumonia Transferred BA B 6 78 8 8 125 >250 32 4 <=0,5 
4145 23/07/2007 CR-ICU 90/M 
Acute 
myocardial 
infarction 
  Exitus BA B 6 78 16 8 125 125 32 8 <=0,5 
4144 24/07/2007 CR-ICU 70/F 
Respiratory 
failure 
  Exitus BA  B 6 78 8 8 64 16 32 4 <=0,5 
4136 30/07/2007 CR-ICU 84/F 
Respiratory 
failure 
  Exitus BA B 6 78 16 4 125 125 32 4 <=0,5 
3966 01/08/2007 CR-ICU 51/M Renal ptosis Sepsis Transferred BC B 6 78 32 8 125 125 32 4 <=0,5 
4146 02/08/2007 CR-ICU 53/F 
Respiratory 
failure 
  Exitus BA B 6 78 8 4 125 16 32 4 <=0,5 
4147 04/08/2007 CR-ICU 70/M 
Respiratory 
failure 
  Exitus BA B 6 78 32 16 125 125 32 4 <=0,5 
3967 03/09/2007 CR-ICU 77/F 
Respiratory 
failure 
  Transferred BA B 6 78 8 8 125 125 32 4 <=0,5 
4148 03/09/2007 CR-ICU 70/M 
Respiratory 
failure 
  Exitus BA B 6 78 16 8 125 >250 32 2 <=0,5 
4149 05/09/2007 CR-ICU 58/F 
Respiratory 
failure 
Pneumonia Exitus BA B 6 78 8 4 125 125 32 4 <=0,5 
4150 10/09/2007 CR-ICU 76/F 
Respiratory 
failure 
  Exitus BA B 6 78 16 8 125 125 32 4 <=0,5 
3974 12/09/2007 CR-ICU 72/M 
Respiratory 
failure 
Sepsis Exitus BC B 6 78 8 4 125 16 32 4 <=0,5 
4151 01/10/2007 CR-ICU 77/M 
Respiratory 
failure 
  Exitus BA B 6 78 16 16 64 125 32 4 <=0,5 
4152 12/10/2007 CR-ICU 63/M 
Respiratory 
failure 
  Exitus BA B 6 78 8 4 125 >250 8 4 <=0,5 
3950 12/10/2007 PO-ICU 72/M 
Respiratory 
failure 
  Exitus BA B 6 78 8 4 64 16 32 4 <=0,5 
3911 24/10/2007 CR-ICU 74/M 
Respiratory 
failure 
Sepsis 
Voluntary 
discharge 
BC B1 6 78 32 8 125 >250 64 4 <=0,5 
4153 03/11/2007 CR-ICU 69/F 
Respiratory 
failure 
  Exitus BA B 6 78 8 8 125 125 64 4 <=0,5 
3909 05/11/2007 CR-ICU 44/F 
Respiratory 
failure 
Pneumonia* Exitus BA B 6 78 32 8 125 2 32 4 <=0,5 
3951 14/11/2007 PO-ICU 49/M 
Pancreatic 
cancer 
  Exitus BA B 6 78 16 8 125 2 256 2 <=0,5 
4154 19/11/2007 CR-ICU 62/M 
Respiratory 
failure 
Pneumonia Exitus BAL B 6 78 16 8 125 2 32 4 <=0,5 
3952 24/11/2007 PO-ICU 79/M 
Abdominal 
aortic 
aneurysm 
Sepsis Exitus BC B 6 78 16 8 125 2 32 4 <=0,5 
3912 22/10/2007 CR-ICU 45/M 
Acute 
myocardial 
infarction 
  Exitus BA B 6 78 8 8 125 >250 32 4 <=0,5 
                                Cotugno Hospital 
3678 07/04/2007 ICU 60/M 
Respiratory 
failure 
Pneumonia Discharge BA B 6 78 32 16 125 125 4 4 <=0,5 
3679 24/05/2007 ICU 75/M 
Cholangiocar
cinoma 
Sepsis Discharge BC B 6 78 16 8 125 125 32 4 <=0,5 
3701 06/06/2007 ICU 60/F Sepsis   Exitus BC B 6 78 16 8 125 125 32 4 <=0,5 
3696 03/10/2007 ICU 60/F Tetanus*   Discharge CVC B 6 78 16 8 125 >250 64 4 <=0,5 
                             Cardarelli Hospital 
3933 04/02/2007 ICU 19/M Polytrauma Sepsis Discharge BC B 6 78 1 0,5 125 32 32 4 <=0,5 
  
 
TABLE 1. Antibiotic susceptibility profiles of A. baumannii isolates of 
PFGE types A and B from the V. Monaldi hospital a. 
a A. baumannii isolates were analyzed by a microdilution method for MIC 
determination according  to CSLI guidelines. MIC values were expressed as mg/liter. 
 
 
Molecular analysis of carbapenem resistance in A. baumannii 
isolates.  
PCR and sequence analysis identified a blaOXA-58 gene flanked by ISAba2 
and ISAba3 elements at the 5’ and 3’ ends, respectively, in plasmid DNA 
from all carbapenem-resistant A. baumannii ST/2A and ST/78B 
isolates, but not from the single carbapenem-susceptible A. baumannii 
strain of PFGE type B isolated in A. Cardarelli hospital. No amplification 
products were obtained from chromosomal or plasmid DNA of A. 
baumannii ST/2A and ST/78B isolates using primers for blaIMP-type, 
blaVIM-type, or blaSIMtype MBLs or blaOXA-23 or blaOXA-24/40 
CHDLs. Also, PCR experiments failed to identify any IS element 
upstream of the naturally occurring blaOXA-66 or blaOXA-90 genes in A. 
baumannii isolates of ST/2A and ST/78B profile, respectively, thus 
 PFGE A (total strains 14) PFGE B (total strains 57) 
Antibiotic MIC50 MIC90 Range MIC50 MIC90 Range 
Sulbactam-ampicillin 32 125 32 – 125 125 125 64 – 125 
Piperacillin-
tazobactam 
125 250 125 - >250 250 250 32 - >250 
Ceftazidime 250 250 125 - >250 250 250 125 - >250 
Cefepime 125 250 16 – 250 16 32 16 – 250 
Imipenem 16 32 8 – 32 16 32 8 – 32 
Meropenem 8 16 4 – 16 8 16 4 – 16 
Amikacin 125 >250 4 - >250 125 >250 2 - >250 
Gentamicin 8 64 4 - >250 32 64 4 - >250 
Ciprofloxacin 64 250 32 - >250 64 250 32 - >250 
Rifampicin 4 500 2 – 500 4 4 2 – 16 
Colistin <0,5 <0,5 <0,5 <0,5 <0,5 <0,5 – 1 
excluding that IS-mediated overexpression of these oxacillinases may 
account for the resistance to imipenem [79].  
 
Genetic location and characterization of the genetic structures 
surrounding the blaOXA-58 gene.  
Digestion of plasmid DNA from A. baumannii isolates of ST/2A and 
ST/78B profile with HindIII enzyme revealed different restriction 
patterns, that generated two different positive bands of approximately 
3.0 and 2.7-kb, and 2.7 and 1.0-kb, respectively, when hybridization 
with a blaOXA-58-specific probe (Fig. 3A). The direct sequence of 
amplicons generated from plasmid DNA preparation of A. baumannii 
ST/2A and ST/78B isolates using primers spanning the 5’ end of A. 
baumannii origin of plasmid replication (oriV) and the 3’ end of ISAba3 
element identified two similar fragments of 6095 and 6073-bp, that 
were designated pABNA1 and pABNA2, respectively. The two amplicons 
showed identical origin of replication (oriV), a repeat region composed of 
five 22-bp-long imperfect direct iterons in pABNA1 and four 22-bp-long 
iterons in pABNA1 and pABNA2, respectively, identical repAci1 and 
repAci2 replicase genes, and a single copy of the blaOXA-58 gene that was 
flanked by ISAbA2 and ISAba3 elements at the 5’ and 3’ ends, 
respectively (Figure 3B). Filter-mating experiments demonstrated that 
resistance to imipenem, along with the blaOXA-58 gene, was transferred 
from A. baumannii isolate 3957 of PFGE type B, but not from A. 
baumannii isolate 3979 of PFGE type A, to imipenem-susceptible 
Acinetobacter genomic species 3 isolate 4442 at a frequency of 1 x 10-6. 
Imipenem MICs for transconjugants were similar (16 mg/liter) to those 
for donor isolates. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. (A) Plasmid localization of the blaOXA-58  gene in A. baumannii isolates of 
PFGE groups A and B. Agarose (1%) gel electrophoresis in 1X Tris-acetate-
EDTA buffer of HindIII-digested plasmids from A. baumannii isolates, stained 
with ethidium bromide and visualized under UV light, and Southern blot 
hybridization with the blaOXA-58 probe are shown. M is a 1-kb DNA ladder 
(Promega, Milan, Italy). (B) Schematic map of the genetic structure 
surrounding the blaOXA-58  gene in A. baumannii isolates of PFGE groups A and 
B. The genes and their corresponding transcription orientations are indicated 
by horizontal arrows. IS elements are represented by empty rectangle boxes 
filled with black arrows indicating the transposase gene and the direction of 
the transcription. Names of relevant features are reported below or above the 
map. 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
In the present report, we studied the molecular epidemiology and the 
genetic basis of carbapenem resistance in A. baumannii strains isolated 
between May 2006 and December 2007 during an epidemic occurred in 
two ICUs of the V. Monaldi hospital in Naples. In accordance with 
previous data [1,62], isolation rate of A. baumannii was significantly 
associated with length of stay in the ward, being higher in CR-ICU than 
PO-ICU [1,62]. Based on a previous study on an A. baumannii outbreak 
occurred in the same institution between June 2003 and June 2004 
[65], we could assume that the epidemic described herein was caused 
by the spread of a single epidemic clone. However, the present report 
revealed the emergence of two distinct A. baumannii epidemic clones, 
that were isolated in two consecutive temporal clusters in the same 
wards of the hospital. Indeed, the identity of 3LST, ST and resistance 
profile/genes and near-identity of PFGE profiles indicate that these two 
sets of isolates each represent a clone. The first epidemic clone showed 
identical PFGE profile of the A. baumannii strains responsible of two 
epidemics occurred in Naples in the Federico II and V. Monaldi 
hospitals during 2002 and 2003-2004, respectively [65,71], and was 
assigned to 3LST group 1 and ST2, that corresponded to the previously 
characterized European clone II [1,50]. The second epidemic clone, that 
was first isolated in CR-ICU ward in May 2006 and replaced the 
previous clone in both wards since March 2007, showed a distinct 
genotype, that was assigned to a novel 3LST group 6 and ST78, that 
has never been isolated before and is described for the first time herein. 
This is consistent with previous studies showing that carbapenem-
resistant A. baumannii epidemics in Southern Europe are caused by 
genotypes belonging to 3LST groups 1 and 2, corresponding to the 
European clones II and I, respectively, but also by additional genotypes 
of 3LST groups 4 and 5 [1,23,62,92]. Our data are also in agreement 
with a recent report showing that four distinct clones are responsible 
for a cluster of carbapenem-resistant A. baumannii infections in the ICU 
of a Greek hospital [70]. Also, the isolation of A. baumannii ST78/B 
strains in the ICUs of two other hospitals in Naples during 2007 
suggests that the spread of the novel A. baumannii epidemic clone 
described herein might have been caused by inter-hospital transfer of 
colonized patients in the city. In agreement with previous studies, the 
respiratory tract was the most frequent site of isolation for both clones 
[50,62,65,71]. However, ST78/B strains caused a higher but not 
statistically significant proportion of bacteremias compared to the other 
clone, thus suggesting that the novel epidemic clone may possess some 
inherent properties to develop invasive disease. Several studies 
demonstrate that A. baumannii epidemic strains are selected in the 
hospital setting because of their multiple antimicrobial resistance 
[50,70,74,115,118]. In particular, the emergence of carbapenem 
resistance has been reported during hospital outbreaks of multidrug-
resistant A. baumannii in Italy and Southern Europe 
[65,66,70,71,89,92,110,113,115,118]. Accordingly, the two A. 
baumannii clones described in the present study showed a similar 
antibiotype, characterized by resistance to all classes of antimicrobials 
including carbapenems, intermediate resistance to rifampin, but 
susceptibility to colistin. Additional epidemiological information was 
provided by molecular analysis of carbapenem resistance genes. A 
plasmid-borne blaOXA-58 gene was identified in both A. baumannii clones 
isolated in the V. Monaldi hospital, but not in the single carbapenem-
susceptible A. baumannii isolate of PFGE type B isolated in A. Cardarelli 
hospital. Although the plasmids carrying the blaOXA-58 gene from the two 
epidemic clones showed distinct restriction patterns, two similar 
amplicons containing an origin of plasmid replication, a repeat region 
composed of four or five 22-bp imperfect direct iterons, the replicase 
genes and a single copy of the blaOXA-58 gene flanked by ISAba2 and 
ISAba3 sequences at the 5’ and 3’ ends of the gene, respectively, were 
identified. The above genetic structures were highly homologous with 
those found in plasmids pOUR and pACICU1 from A. baumannii strains 
183 and ACICU, respectively, isolated in Rome, Italy [73,113]. 
Interestingly, all A. baumannii strains carrying the blaOXA-58 gene 
isolated in Rome were assigned to ST group 1 and European clone II 
[73,89,113] as like as the A. baumannii strains responsible for the 
outbreak occurred in the V. Monaldi hospital during 2003 and 2004 
[65,92]. A blaOXA-58 gene flanked by ISAba2 and ISAba3 sequences has 
been also found in plasmids isolated in strains from France and Spain 
showing distinct pulsotype [68] and in plasmids isolated in strains from 
Greece assigned to ST groups 1 and 2 [92]. The above all data suggest 
that carbapenem resistance in the two A. baumannii epidemic clones 
might have been acquired through horizontal gene transfer among 
distinct clones. Because clone ST2/A carrying a plasmid-borne blaOXA-58 
gene was first isolated in the V. Monaldi hospital during 2003 [65] while 
the first isolation of clone ST78/B carrying a plasmid-borne blaOXA-58 
gene occurred during 2006 in the hospital and one carbapenem-
susceptible A. baumannii strain with ST78/B profile was isolated in 
another hospital of Naples during 2007, we can make the hypothesis 
that plasmid sequences carrying the blaOXA-58 gene flanked by ISAba2 
and ISAba3 elements were transferred from clone ST2/A to clone 
ST78/B. In further support of this, we demonstrated herein that 
resistance to imipenem, along with the blaOXA-58 gene, was transferred 
from ST78/B strains into imipenem-susceptible Acinetobacter genomic 
species 3 strain.  
In conclusion, molecular epidemiology of A. baumannii in the V. Monaldi 
hospital showed the occurrence of a novel epidemic clone that 
successfully spread among different wards and was selected because of 
the presence of a plasmid-borne blaOXA-58 gene. This emphasizes the 
need to study the global epidemiology of A. baumannii and its 
associated antimicrobial resistances using molecular typing methods in 
order to control the epidemic spread of multidrug-resistant A. 
baumannii infections in the hospital setting.  
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ABSTRACT  
 
Acinetobacter baumannii is an opportunistic gram-negative pathogen 
with increasing relevance in a variety of nosocomial infections especially 
among intensive-care-unit (ICU) patients. Carbapenems have been 
widely used to treat serious multidrug-resistant A. baumannii 
infections; however, incidences of carbapenem-resistant A. baumannii 
are rising in several parts of the world and large and sustained 
outbreaks caused by such bacteria have been described. Carbapenem-
resistant A. baumannii epidemics are sustained by clusters of highly 
similar strains that successfully spread among different cities and 
countries; their resistance phenotype is mainly due to the acquisition of 
carbapenem-hydrolyzing class D β-lactamase (CHDL) genes flanked by 
insertion sequence (IS) elements. Multi-facility outbreaks can be also 
sustained by inter-hospital transfer of colonized patients. Here, we 
review the global epidemiology of carbapenem-resistant A. baumannii, 
with the emphasis on the molecular epidemiology and genetic 
characterization of carbapenem resistance in epidemic strains. 
 
INTRODUCTION  
 
Acinetobacter spp. are glucose-non fermentative gram-negative 
coccobacilli that have emerged in recent years as a cause of healthcare-
associated infections [1,62]. Considered to be commensals of low-grade 
pathogenicity, i.e. opportunistic microorganisms, Acinetobacter were 
frequently ignored in the 1970s whenever isolated from clinical 
specimens [1]. The genus Acinetobacter currently contains up to 32 
described named and unnamed (genomic) species [1]. Acinetobacter 
baumannii, genomic species 3 and 13TU, three of the most clinically 
relevant species, are genetically and phenotypically very similar to an 
environmental species, A. calcoaceticus, and are therefore grouped 
together into the so-called A. calcoaceticus-A. baumannii (Acb) complex 
[1]. Because phenotypic identification of Acinetobacter isolates to the 
species level has proven to be insufficient, several genotypic methods 
have been developed for genomic species identification, that include 
amplified 16S rRNA gene restriction analysis (ARDRA), high-resolution 
fingerprint analysis by amplified fragment length polymorphism (AFLP), 
or sequence analysis of the 16S-23S rRNA gene spacer region [1,57,59]. 
However, genotypic methods for species identification are often 
unavailable in developing countries, where Acinetobacter are frequently 
isolated but identified only at genus level. The species that is most 
commonly involved in hospital infections is A. baumannii, which causes 
a variety of health-care associated infections, comprising bacteremia, 
urinary tract infection, surgical-site infection, and nosocomial and 
ventilator-associated pneumonia, especially in intensive-care-unit (ICU) 
patients [1,62,65,76,77]. The rates of recovery of A. baumannii from 
natural environments and its incidence in the community are low, while 
its rate of carriage by hospitalized patients is high and its occurrence in 
the hospital setting is frequent [1]. A. baumannii has simple growth 
requirements and can survive in dry conditions. This might contribute 
to the fitness of A. baumannii in the hospital environment, which 
represents the main reservoir of the bacterium [1]. 
 
Carbapenem resistance mechanisms in A. baumannii  
Resistance to antimicrobial agents may be the main advantage of A. 
baumannii in the nosocomial environment. Multidrug-resistant isolates 
of A. baumannii have been reported increasingly during the last decade, 
probably as a consequence of extensive use of antimicrobial agents in 
western countries [62,78]. Also, as recently demonstrated by a 
retrospective, matched cohort study, patients with infection by 
multidrug-resistant Acinetobacter show higher mortality rate and length 
of hospitalization than patients with infection by susceptible 
Acinetobacter [76].  
Mounting evidence indicates that A. baumannii possesses a broad range 
of mechanisms of resistance to all existing antibiotic classes as well as a 
prodigious capacity to acquire new determinants of resistance [1,62] 
Genome sequence analysis of six A. baumannii clinical strains has 
shown the presence of a resistance island with a variable composition of 
resistance genes interspersed with transposons, integrons, and other 
mobile genetic elements in three of them [79-81]. Also, plasmids 
carrying resistance genes and/or resistance determinants involved in 
horizontal gene transfer have been described in several A. baumannii 
strains [63,66,68,82-86].  
The broad-spectrum β-lactam antibiotics, carbapenems, were 
introduced by 1985 and have been for years the most important agents 
for the treatment of infections caused by multidrug-resistant A. 
baumannii. Carbapenem resistance in Acinetobacter is now observed 
increasingly worldwide, and constitutes a sentinel event for emerging 
antimicrobial resistance [62,82]. Carbapenem-resistant isolates of A. 
baumannii are usually resistant to all classes of antimicrobials, and 
show intermediate resistance to rifampin, while usually retaining 
susceptibility to tigecycline and colistin [62,82,87]. Resistance against 
carbapenems is, in itself, considered sufficient to define an isolate of A. 
baumannii as highly resistant [82]. The resistance of A. baumannii to 
carbapenems can be mediated by one of the resistance mechanisms 
that are known to occur in bacteria, including enzymatic inactivation, 
active efflux of drugs, and modification of target sites (Table 1). The 
production of carbapenem-hydrolizing beta-lactamases is the most 
common mechanism responsible for carbapenem resistance in A. 
baumannii. Several carbapenem-hydrolyzing β-lactamases have been 
identified so far in A. baumannii. These include metallo-β-lactamases 
(VIM-, IMP- and SIM-types), which have been sporadically reported in 
some parts of the world and have been associated with class 1 integrons 
[62,77,82]. Nevertheless, the most widespread carbapenemases in A. 
baumannii are class D β-lactamases. Three main acquired carbapenem-
hydrolysing class D oxacillinase (CHDL) gene clusters have been 
identified either in the chromosome or in plasmids of A. baumannii 
strains, represented by the blaOXA-23-, blaOXA-24/40-, and blaOXA-58-like genes 
[82]. Different insertion sequence (IS) elements at the 5’ and/or the 3’ 
end of blaOXA-23-, and blaOXA-58-like genes, such as ISAba1, ISAba2, 
ISAba3, or IS18, have been demonstrated to regulate their expression 
[66,68,78,83,84]. Also, it has been recently demonstrated that the 
ISAba1 element is capable of transposition in E. coli and of mobilizing 
an antibiotic resistance gene [85]. In addition to these CHDL genes, the 
chromosomal blaOXA-51-like gene, intrinsic to A. baumannii species, has 
been demonstrated to confer carbapenem resistance when an ISAba1 
element is inserted upstream of the gene [86]. Reduced susceptibility to 
carbapenems has also been associated with the modification of 
penicillin-binding proteins and porins or with upregulation of the 
AdeABC efflux system, and it has been suggested that the interplay of 
different mechanisms might result in high-level carbapenem resistance 
in A. baumannii (Table 1) [88-90]. 
 
Table 1.Carbapenem mechanisms in A. baumannii. 
 
 
 
 
 
 
Global epidemiology of carbapenem-resistant Acinetobacter 
baumannii  
Carbapenem resistance in A. baumannii is now an emerging issue 
worldwide [62]. Surveillance studies indicate that the percentage of 
carbapenem-resistant isolates gradually increased over the last ten 
years in Europe, North America, and Latin America [62]. Numerous 
outbreaks of carbapenem-resistant A. baumannii were reported from 
hospitals in Northern Europe (Spain, Portugal, France, the United 
Kingdom (UK), the Netherlands, Czech Republic, Poland) [1,26,62,91-
95], Southern Europe and the Middle East (Bulgaria, Greece, Italy, 
Turkey, Lebanon, Israel, Iran, Iraq and United Arab Emirates) 
[62,63,65,68,77,78,80,82,84,96-101], North America and Latin America 
(Argentina, Brazil, Chile and Colombia) [62,102,103], Tunisia and South 
Africa [104,105], China, Taiwan, Singapore, Hong Kong, Japan, South 
Korea [62,106,107], and Australia [108] and from areas as remote as 
French Polynesia [109]. In the majority of cases, one or two epidemic 
strains were detected in a given hospital. Transmission of such strains 
was observed between hospitals in the same city and also on a national 
scale [1,26,62,65,82,91-93,95,96,104,108,110-112] and a direct 
epidemiological link was established in several cases 
[26,65,94,95,104,108,110-112]. The inter-hospital transfer of colonised 
patients was demonstrated during multi-facility outbreaks that 
occurred in the Netherlands [26], Italy [65], South Africa [104], and 
Tunisia [105]. The international transfer of patients colonised by 
carbapenem-resistant A. baumannii was also reported [94,95,108]. More 
recently, several cases of United Kingdom and US military and 
nonmilitary personnel returning from operations in Iraq and 
Afghanistan and harbouring infections caused by carbapenem-resistant 
A. baumannii were reported [110-112] (Figure 1).  
Outbreaks caused by carbapenem-resistant A. baumannii have also 
been observed in developing countries such as Morocco, Thailand, 
India, and Indonesia [113,107]. Furthermore, infections caused by 
Acinetobacter spp. without specifying whether they are caused by 
carbapenem-resistant strains have been reported in Africa (Lagos, 
Nigeria) and several Asian countries including Nepal [114-116]. 
 
Molecular epidemiology of carbapenem-resistant 
Acinetobacter baumannii  
Genotypic characterization of carbapenem-resistant A. baumannii 
strains showed the occurrence of blaOXA-23-, blaOXA-24/40-, or blaOXA-58-like 
genes in multiple isolates from the same hospital or among different 
hospitals worldwide [62,82,68,99,100,109,118]. blaOXA-23 was mostly 
detected in isolates from Asian countries [107], but was also reported in 
South America [102,103] and Europe [82,84,97,117]; blaOXA-58 was 
frequently found in Europe [65,77,80,63,96,99,66,96-101,117]. blaOXA-
24/40 was mostly found in the Iberian peninsula and Asia, but also 
detected in Iran, Belgium, Czech Republic and the United States of 
America (USA) [62,92,93,107,110,117,118] (Figure 1). Molecular 
epidemiology of A. baumannii strains responsible for outbreaks that 
occurred in several European hospitals revealed clusters of highly 
similar strains, which were defined as European clones I and II [1,62] 
and corresponded to sequence type (ST) groups 2 and 1, respectively, 
identified by sequence-based typing [23]. A recent study on a collection 
of 96 carbapenem-resistant A. baumannii strains collected in 17 
European countries assigned 85% of them to sequence type (ST) groups 
1 and 2 by multiple PCRs [117]. The prevalence of carbapenem-
resistant epidemic A. baumannii strains belonging to ST group 1 was 
also demonstrated in Italy and Greece [96,99] along with the spread of a 
prevalent clone isolated with identical pulsed field gel electrophoresis 
(PFGE) profiles in two hospitals in Naples, Italy, and in three hospitals 
in three distinct Greek cities [99]. The circulation of distinct 
carbapenem-resistant A. baumannii genotypes belonging to ST group 2 
in Greece and in Lebanon, and to two novel ST groups 4 and 5 in 
different Greek and Turkish cities, was also shown in the same study 
[99]. The blaOXA-58 gene flanked by IS elements was present in all 
carbapenem-resistant genotypes analyzed from hospitals in Greece, 
Italy, Lebanon, and Turkey [77,66,99] (Figure 1). Of note, each of the IS 
elements flanking the 5’ end of blaOXA-58 occurred in strains of distinct 
ST groups and PFGE profiles isolated in the same geographic region. 
Thus, ISAba2 element was detected in Greece and Italy, IS18 in 
Lebanon and Turkey, and ISAba1 in Turkey and Italy, suggesting that 
they might have been acquired through horizontal gene transfer [99]. In 
further support of this hypothesis, plasmid-borne blaOXA-58 has been 
found in the majority of carbapenem-resistant A. baumannii strains 
isolated in Europe [65,77,80,68,63,66,99]. The spread of carbapenem-
resistant A. baumannii carrying the blaOXA-58 gene might had also been 
contributed by international transfer of colonised patients, as recently 
demonstrated from Greece to Belgium [94], Greece to Australia [108], 
and Iraq to USA military services [110] (Figure 1). 
 
 
 
 
Geographic distribution and genetic characterization of carbapenem-resistant 
A. baumannii. Countries reporting carbapenem-resistant A. baumannii 
outbreaks producing OXA-23-, OXA-24/40-, and/or OXA-58-type enzymes are 
indicated by yellow, blue, and red colours, respectively. Countries reporting 
carbapenem-resistant A. baumannii outbreaks in which the OXA-type enzyme 
has not been identified are indicated by green colour. Green arrows indicate 
hospital transfer of colonized/infected patients by carbapenem-resistant A. 
baumannii between different countries.  
 
 
 
CONCLUSIONS  
 
Outbreaks of carbapenem-resistant A. baumannii are increasingly 
reported in several parts of the world that also include developing 
countries. They are sustained by clusters of highly similar strains that 
successfully spread among different cities and countries and are 
selected because of the acquisition of CHDLs genes flanked by IS 
elements. Multi-facility A. baumannii outbreaks can be also sustained 
by inter-hospital transfer of colonized patients. This emphasizes the 
need to adopt surveillance and infection control programmes to prevent 
colonisation and infection by multidrug-resistant A. baumannii in the 
hospital setting. These programmes would include the study of global 
epidemiology of multidrug-resistant A. baumannii using molecular 
typing of bacterial isolates and characterization of antibiotic resistance 
in order to control the spread of A. baumannii infections over a wide 
geographic region.  
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Nucleotide Plasmid Sequences pABNA1and pABNA2 
deposited in the Genbank Nucleotide Database  
 
  
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GenBank: GQ338082.1 
Acinetobacter baumannii plasmid pABNA1 RepAci1 (repAci1) 
and RepAci2 (repAci2) genes, complete cds; insertion 
sequence ISAba3 tnpA gene, partial cds; insertion sequence 
ISAba2 insA (insA) and insB (insB) genes, complete cds; 
insertion sequence ISAba3 tnpA gene... 
 
LOCUS       GQ338082                6095 bp    DNA     linear   BCT 
05-AUG-2009 
DEFINITION  Acinetobacter baumannii plasmid pABNA1 RepAci1 (repAci1) 
and RepAci2 (repAci2) genes, complete cds; insertion sequence ISAba3 
tnpA gene, partial cds; insertion sequence ISAba2 insA (insA) and insB 
(insB) genes, complete cds; insertion sequence ISAba3 tnpA gene, 
partial cds; OXA-58 (blaOXA-58) gene, complete cds; and insertion 
sequence ISAba3 tnpA gene, partial cds. 
ACCESSION   GQ338082 
VERSION     GQ338082.1  GI:254972045 
KEYWORDS    . 
SOURCE      Acinetobacter baumannii 
  ORGANISM  Acinetobacter baumannii 
            Bacteria; Proteobacteria; Gammaproteobacteria; 
Pseudomonadales; 
            Moraxellaceae; Acinetobacter. 
REFERENCE   1  (bases 1 to 6095) 
  AUTHORS   Zarrilli,R. and Giannouli,M. 
  TITLE     Molecular epidemiology of multi-drug resistant 
Acinetobacter 
            baumannii in a tertiary care Hospital in Naples, Italy, 
shows the 
            emergence of a novel epidemic clone 
  JOURNAL   Unpublished 
REFERENCE   2  (bases 1 to 6095) 
  AUTHORS   Zarrilli,R. and Giannouli,M. 
  TITLE     Direct Submission 
  JOURNAL   Submitted (30-JUN-2009) Preventive Medical Sciences, 
University of 
            Naples 'Federico II', Via S. Pansini nr. 5, Napoli 80131, 
Italy 
FEATURES             Location/Qualifiers 
     source          1..6095 
                     /organism="Acinetobacter baumannii" 
                     /mol_type="genomic DNA" 
                     /strain="3979" 
                     /db_xref="taxon:470" 
                     /plasmid="pABNA1" 
     rep_origin      1..180 
                     /standard_name="oriV" 
                     /direction=RIGHT 
     repeat_region   181..202 
                     /function="control of DNA replication" 
                     /rpt_family="iteron" 
                     /rpt_type=direct 
                     /rpt_unit_range=181..202 
                     /rpt_unit_seq="atatgtccacgtttaccttgca" 
     repeat_region   203..224 
                     /function="control of DNA replication" 
                     /rpt_family="iteron" 
                     /rpt_type=direct 
                     /rpt_unit_seq="atatgtccacgtttaccttgca" 
     repeat_region   225..246 
                     /function="control of DNA replication" 
                     /rpt_family="iteron" 
                     /rpt_type=direct 
                     /rpt_unit_seq="atatgtccacgtttaccttgca" 
     repeat_region   247..268 
                     /function="control of DNA replication" 
                     /rpt_family="iteron" 
                     /rpt_type=direct 
                     /rpt_unit_seq="atatgtccacgtttaccttgca" 
     repeat_region   269..290 
                     /function="control of DNA replication" 
                     /rpt_family="iteron" 
                     /rpt_type=direct 
                     /rpt_unit_seq="atatgtccacgtttaccttgca" 
     gene            344..1294 
                     /gene="repAci1" 
     CDS             344..1294 
                     /gene="repAci1" 
                     /note="replicase; plasmid replication protein" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="RepAci1" 
                     /protein_id="ACT98244.1" 
                     /db_xref="GI:254972046" 
                     
/translation="MRDLVVKDNALINASYNLDLVEQRLILLAIVEARESGKGINAND 
                     
PLEVHADSYINQFGVHRNTAYQALKDACKDLFARQFSYQEKKANGNIRNVMSRWVSQI 
                     
AYNDNEATVDLIFAPAVVPFITRLEEQFTKYELQQVSSLSSAYAIRLYELLIQWRSTG 
                     
KTPTIELQEFRKKLGVLDNEYLRMAHLKERVLELSIKQINEHTDITVKYEQHKRGRSI 
                     
SGFSFTFKQKKKDSPSIERDPNTLELFSKMTDAQRHMFANKLSELPEMGRYSQGTESY 
                     QQFAVRIAEMLQDPAQFKELYPYLKKVGYMPSNKKDTVNG" 
     gene            1287..1862 
                     /gene="repAci2" 
     CDS             1287..1862 
                     /gene="repAci2" 
                     /note="replicase; DNA replication protein" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="RepAci2" 
                     /protein_id="ACT98245.1" 
                     /db_xref="GI:254972047" 
                     
/translation="MAKLSLSEVSKKFHVDRSTIYRAVRNGRLSRSSDGQFDLAEVIR 
                     
CFGEPEQTSQKIESSKQEGDESTKKLIAHLENEVKKYQEREERLMQQIDRMQTLIELK 
                     
SVAPATAAPHQDATACDTKMPQHATTQQDTDNKKNNELNIAENVAVPQQETTAYHTQT 
                     LQHATLQSVAVPQHKKRGLFGRVLNAVFDND" 
     repeat_region   2872..3285 
                     /note="truncated due to the insertion of ISAba2" 
                     /mobile_element="insertion sequence:ISAba3" 
     CDS             complement(2905..>3285) 
                     /note="transposase; disrupted due to ISAba2 
insertion" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="truncated TnpA" 
                     /protein_id="ACT98246.1" 
                     /db_xref="GI:254972048" 
                     
/translation="KVDGKQNYQCKDCKRQFIGDHALSYLGCKSGITRKILQLMVRGS 
                     
GIRDIAEVERISIGKVLRTLTESTYEIQPQQSHYESLEVDEFWNFVGNKKNKQWLIFV 
                     QKSYFTSEKPDIFIGENIDTLNGF" 
     repeat_region   3286..4591 
                     /mobile_element="insertion sequence:ISAba2" 
     repeat_region   3286..3310 
                     /rpt_type=inverted 
     gene            3335..3652 
                     /gene="insA" 
     CDS             3335..3652 
                     /gene="insA" 
                     /note="transposase" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="insA" 
                     /protein_id="ACT98247.1" 
                     /db_xref="GI:254972049" 
                     
/translation="MTKPKYTPEIRDRAVQLLIESEKDYPSNWAAITAIAPKIGCTPE 
                     
TLRVWYLKHLDQQNPIKVQQASDQEKMKQMEREIKELKRANEILRKAAAFFAQAELDR 
                     PHK" 
     gene            3652..4554 
                     /gene="insB" 
     CDS             3652..4554 
                     /gene="insB" 
                     /note="transposase" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="insB" 
                     /protein_id="ACT98248.1" 
                     /db_xref="GI:254972050" 
                     
/translation="MVDFIHNNKDLYGVDAICRILPIAASTYYRTLDLADNPEHRAKR 
                     
DLHDLHHAEQIKRIWKESSGRYGVRKVWQKLKREGYIIARCTVARLMQKLGIQGVWRG 
                     
KNKQTTHSRDDQKRADDLVKRNFSADHPDQLWVADFTYIQTNSGWVYTAFIIDVFSRA 
                     
IVGWKVSTRMNTDMVLDALEQALHDRGMPKNVIHHSDRGVQYLSIRYTNRLEAANLRA 
                     
SVGTTGDSYDNALAETVNGLYKTEVIEYLKADWQGLADVQLATLNWVDWFNKERVHSA 
                     LGYVSPFDFEAMYYDKINPLGQVA" 
     repeat_region   4567..4591 
                     /rpt_type=inverted 
     CDS             complement(<4592..4662) 
                     /note="transposase" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="truncated TnpA" 
                     /protein_id="ACT98249.1" 
                     /db_xref="GI:254972051" 
                     /translation="MQITLAIKCPTCLSDSIKKNGIKV" 
     repeat_region   4592..4662 
                     /note="transposase; disrupted due to ISAba2 
insertion" 
                     /mobile_element="insertion sequence:ISAba3" 
     repeat_region   4699..4725 
                     /rpt_type=inverted 
     gene            4743..5585 
                     /gene="blaOXA-58" 
     CDS             4743..5585 
                     /gene="blaOXA-58" 
                     /note="carbapenem-hydrolyzing oxacillinase" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="OXA-58" 
                     /protein_id="ACT98250.1" 
                     /db_xref="GI:254972052" 
                     
/translation="MKLLKILSLVCLSISIGACAEHSMSRAKTSTIPQVNNSIIDQNV 
                     
QALFNEISADAVFVTYDGQNIKKYGTHLDRAKTAYIPASTFKIANALIGLENHKATST 
                     
EIFKWDGKPRFFKAWDKDFTLGEAMQASTVPVYQELARRIGPSLMQSELQRIGYGNMQ 
                     
IGTEVDQFWLKGPLTITPIQEVKFVYDLAQGQLPFKPEVQQQVKEMLYVERRGENRLY 
                     
AKSGWGMAVDPQVGWYVGFVEKADGQVVAFALNMQMKAGDDIALRKQLSLDVLDKLGV 
                     FHYL" 
     repeat_region   5596..>6095 
                     /mobile_element="insertion sequence:ISAba3" 
     repeat_region   5596..5622 
                     /rpt_type=inverted 
     CDS             5676..>6095 
                     /note="transposase" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="tnpA" 
                     /protein_id="ACT98251.1" 
                     /db_xref="GI:254972053" 
                     
/translation="MQITLAIKCPTCLSDSIKKNGIKVDGKQNYQCKDCKRQFIGDHA 
                     
LSYLGCKSGITRKILQLMVRGSGIRDIAEVERISIGKVLRTLTESTYEIQPQQSHYES 
                     LEVDEFWNFVGNKKNKQWLIYAYHRETGEIVAYVWGKR" 
ORIGIN       
        1 gtcacgccag tattaaccaa aaaattgccc caacgaactg agcgaaagcg aagttcaata 
       61 gagtttgagc gaagcgaaaa ccaagggcaa tttttcattc cctgggcttt taattatttt 
      121 aaagttttta aatactttta aatggcttga aagccttatg aataaagggt tttagctctt 
      181 atatgtccac gtttaccttg caatatgtcc acgtttacct tgcaatatgt ccacgtttac 
      241 cttgcaatat gtccacgttt accttgcaat atgtccacgt ttaccttgca ttagtacaca 
      301 aataatatta acgtgtactt atacacaata aaaaatagtg gctatgagag atttagttgt 
      361 aaaggacaat gccttaatca acgcaagcta taacttagac ttagtagaac aacgtttaat 
      421 tttattggct attgttgaag caagggaaag tgggaaaggg attaatgcaa atgatccatt 
      481 agaagttcat gcagatagtt atatcaatca atttggtgta caccgtaata cagcttatca 
      541 agccttaaaa gatgcttgta aggatttatt cgcgcgtcaa tttagctatc aagagaaaaa 
      601 agctaatggg aatatccgaa atgttatgag tcgttgggta tctcaaattg cttataacga 
      661 caatgaagca actgtagact taatatttgc acctgctgtt gttcccttca taacccgact 
      721 ggaagaacaa tttactaaat atgaattaca gcaagttagt agtcttagta gcgcttatgc 
      781 cattcgctta tatgagcttc taattcagtg gcgaagcact ggtaaaaccc caaccataga 
      841 actacaagaa tttagaaaga agttaggcgt tcttgataat gaatatttac ggatggctca 
      901 tttaaaagag cgtgttttag agctttcaat taaacaaata aatgagcata cggatataac 
      961 tgtaaaatat gaacagcata aaagaggacg ttctatttca ggattttctt ttacctttaa 
     1021 acagaagaag aaggatagcc catcaataga aagagatccg aacactttgg agcttttttc 
     1081 aaagatgacc gatgctcaac ggcatatgtt tgcaaataaa ctttcagaac tccctgaaat 
     1141 gggtcgctat tcacaaggaa cagaaagcta ccaacagttt gctgtacgta ttgctgagat 
     1201 gctacaagat cccgctcaat tcaaagagct atacccatac ctaaaaaaag tgggatacat 
     1261 gccatcaaat aaaaaggaca ccgtaaatgg ctaagttatc actaagtgaa gtatctaaaa 
     1321 aatttcatgt ggatagatca accatttaca gagctgtacg taatggacgt ttatcacgct 
     1381 ccagtgatgg acaattcgat ctagcagagg tcatacgatg ctttggagaa cctgagcaaa 
     1441 catctcaaaa aattgaatca tctaagcaag aaggtgatga atctacaaaa aaacttattg 
     1501 cccatttaga aaatgaagtc aaaaaatacc aagaacgtga agaacggtta atgcaacaaa 
     1561 ttgaccgtat gcaaacactc attgagctga aaagtgttgc acctgccaca gcagcaccac 
     1621 accaagatgc tacggcatgc gacaccaaga tgccacagca tgcgacaaca caacaagaca 
     1681 ctgataacaa aaagaataat gaattaaata ttgcagaaaa tgtagcagtg ccacagcaag 
     1741 aaactacggc ataccacacc caaacgctac agcatgccac gttgcaaagt gtggcagtgc 
     1801 cacaacacaa aaaacgtggt ttatttggcc gtgtgctgaa tgccgtcttt gataatgact 
     1861 gagcaataag ggtgaaagat catgccgaaa ctgaaagaca ttgccctggg aattattgta 
     1921 gctccgctgc tgatcccgat catgctgatt gcatcgtacc aggataaaaa ggcgctgaag 
     1981 aaagagctgg atgaatgcca aaaagaaaaa gaccaggcat cctgattatt caattgagct 
     2041 aatcaaaagt gtggaacatt gatgaaataa tagcgtggaa cgtgaaaagt cataaaaaaa 
     2101 gcccgaacag ggatgctcgg gctataaact agaaactaca gcgttgaatt ataaggataa 
     2161 ttatacagca tttcgtataa ggtgtattat gttaatttta ggaaatatta aaactaattt 
     2221 tcagacttat cccaccaact ttgagctaaa tcagtatttt taggaatacc tataccatca 
     2281 cgatacataa cggaaagact tcgcattgct ttcttattac ctaactttgc agccttttca 
     2341 cgaagttcaa aagctttatt aatattaact tctattccgc tatctgcacg agtatataga 
     2401 tcagctaact caaccattga ttcagaatgg ccattttctg aggctttctg aaaccactta 
     2461 aaagcttttt ggaaatgttc taaagaatcg tttttgtcat catcttccat taatctagca 
     2521 taagtaacat atccatcagc taaccaaaac attgctgcta catttccatt ttctgctgat 
     2581 ttaagagccc aaacttcagc ttgattttca tctgaatcaa caccatgacc atatagataa 
     2641 atctcggcta attctaactg agcagaagta tctccatttt ctgctttcgc taataaatca 
     2701 ttagaaaaaa caggttctgc aaatgtttcc attgaaaggc aaactcctaa agccataaaa 
     2761 atatttgtta atttattcaa tttttaacct ttaaactaaa ctgttaggct tgtatatttt 
     2821 tatatcatac ctaaaagaaa actctaaaat tagagtatgt cttatctcta tttaacataa 
     2881 tggctgttat acgaaacgag agtgttagaa cccatttaaa gtgtctatat tctcaccaat 
     2941 aaaaatgtcc ggtttctccg aggtaaaata tgacttttga acaaaaataa gccattgttt 
     3001 attcttttta tttccaacaa aattccagaa ctcatctact tcgagagatt cataatgact 
     3061 ttgctgaggc tgaatttcat aggttgattc agttaaagta cgtaaaactt taccgatact 
     3121 gatgcgctca acttcagcaa tatctcgtat accgctgcct ctgaccatca actgtaatat 
     3181 tttacgagta atacctgact tacatcctag atagctcagt gcatgatcac caataaactg 
     3241 acgtttacag tctttgcact gatagttttg tttcccatct actttgaacc gtaccgggtt 
     3301 tgtcggagac caactttctt gagagaatgt cccgatgaca aaaccaaaat atacccctga 
     3361 aatccgagat agagcggttc aattattgat tgaatccgaa aaagattatc catcgaattg 
     3421 ggctgcaatc actgctattg ctcccaagat aggttgtact cctgaaacac tgcgtgtttg 
     3481 gtatttaaaa catctcgatc aacaaaatcc tatcaaagta caacaggcat cagatcaaga 
     3541 aaaaatgaag cagatggaac gtgaaatcaa agaattaaag cgtgccaatg aaattctacg 
     3601 taaagcagct gcttttttcg cccaggcgga gctcgaccgc ccacacaaat aatggtggat 
     3661 ttcatccata acaataaaga cttatatggt gttgatgcga tttgtaggat tttaccgatc 
     3721 gcagcttcaa cctattaccg aactttagat ctcgcggaca atccagaaca tcgagcgaag 
     3781 cgagatttac atgacttgca tcatgctgaa caaattaaac gaatttggaa ggaaagttca 
     3841 ggtcgatatg gtgtacgtaa agtttggcaa aaactgaaac gtgaaggcta tattattgca 
     3901 cgctgtacag ttgctcgatt gatgcaaaag ctaggtatac aaggtgtttg gcgaggtaag 
     3961 aataaacaaa ctacccatag ccgagatgat caaaaacgag cagatgactt ggtgaaacgc 
     4021 aattttagtg ctgatcaccc tgaccagctg tgggtcgctg actttacgta tattcaaaca 
     4081 aattcaggct gggtctatac cgcctttatt attgatgtgt tctcgcgagc aattgttgga 
     4141 tggaaagtat caacacggat gaatacagac atggtgctcg atgcactgga gcaagcattg 
     4201 catgatcgag gcatgccaaa gaacgtgatt catcatagtg acagaggtgt gcaatatctt 
     4261 tccattcgtt ataccaatcg tttagaagca gcaaatttac gagcatcagt cggtacgacc 
     4321 ggtgattcat acgataatgc tttggctgaa acggtgaatg gcttatacaa aacagaggtg 
     4381 attgaatatt taaaagcgga ttggcaaggt ttagcggatg tacaacttgc gacattaaat 
     4441 tgggtagatt ggttcaataa agagcgtgta catagtgcac taggttatgt gtcacctttt 
     4501 gattttgaag caatgtacta tgataaaatt aacccgttag gtcaggtggc ctaacttaaa 
     4561 taaaaagtct ccgacaaacc cggtacggtt cactttgata ccatttttct ttatactatc 
     4621 actgaggcag gttggacatt tgattgctag agttatttgc atttctctat tttatcaaaa 
     4681 tccaatcggc tttttcttca gcatactttt tgaaacacta ccaaatttta aagttgtata 
     4741 tcatgaaatt attaaaaata ttgagtttag tttgcttaag cataagtatt ggggcttgtg 
     4801 ctgagcatag tatgagtcga gcaaaaacaa gtacaattcc acaagtgaat aactcaatca 
     4861 tcgatcagaa tgttcaagcg ctttttaatg aaatctcagc tgatgctgtg tttgtcacat 
     4921 atgatggtca aaatattaaa aaatatggca cgcatttaga ccgagcaaaa acagcttata 
     4981 ttcctgcatc tacatttaaa attgccaatg cactaattgg tttagaaaat cataaagcaa 
     5041 catctacaga aatatttaag tgggatggaa agccacgttt ttttaaagca tgggacaaag 
     5101 attttacttt gggcgaagcc atgcaagcat ctacagtgcc tgtatatcaa gaattggcac 
     5161 gtcgtattgg tccaagctta atgcaaagtg aattgcaacg tattggttat ggcaatatgc 
     5221 aaataggcac ggaagttgat caattttggt tgaaagggcc tttgacaatt acacctatac 
     5281 aagaagtaaa gtttgtgtat gatttagccc aagggcaatt gccttttaaa cctgaagttc 
     5341 agcaacaagt gaaagagatg ttgtatgtag agcgcagagg ggagaatcgt ctatatgcta 
     5401 aaagtggctg gggaatggct gtagacccgc aagtgggttg gtatgtgggt tttgttgaaa 
     5461 aggcagatgg gcaagtggtg gcatttgctt taaatatgca aatgaaagct ggtgatgata 
     5521 ttgctctacg taaacaattg tctttagatg tgctagataa gttgggtgtt tttcattatt 
     5581 tataagaatt agaagtttga ggttaatcta tttttggtag tgtttcaaaa agtatgctga 
     5641 agaaaaagcc gattggattt tgataaaata gagaaatgca aataactcta gcaatcaaat 
     5701 gtccaacctg cctcagtgat agtataaaga aaaatggtat caaagtagat gggaaacaaa 
     5761 actatcagtg caaagactgt aaacgtcagt ttattggtga tcatgcactg agctatctag 
     5821 gatgtaagtc aggtattact cgtaaaatat tacagttgat ggtcagaggc agcggtatac 
     5881 gagatattgc tgaagttgag cgcatcagta tcggtaaagt tttacgtact ttaactgaat 
     5941 caacctatga aattcagcct cagcaaagtc attatgaatc tctcgaagta gatgagttct 
     6001 ggaattttgt tggaaataaa aagaataaac aatggcttat ttacgcctat catcgagaaa 
     6061 caggtgaaat tgttgcttat gtttggggta aacga 
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and RepAci2 (repAci2) genes, complete cds; insertion sequence ISAba3 
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FEATURES             Location/Qualifiers 
     source          1..6073 
                     /organism="Acinetobacter baumannii" 
                     /mol_type="genomic DNA" 
                     /strain="3957" 
                     /db_xref="taxon:470" 
                     /plasmid="pABNA2" 
     rep_origin      1..180 
                     /standard_name="oriV" 
                     /direction=RIGHT 
     repeat_region   181..202 
                     /function="control of DNA replication" 
                     /rpt_family="iteron" 
                     /rpt_type=direct 
                     /rpt_unit_range=181..202 
                     /rpt_unit_seq="atatgtccacgtttaccttgca" 
     repeat_region   203..224 
                     /function="control of DNA replication" 
                     /rpt_family="iteron" 
                     /rpt_type=direct 
                     /rpt_unit_seq="atatgtccacgtttaccttgca" 
     repeat_region   225..246 
                     /function="control of DNA replication" 
                     /rpt_family="iteron" 
                     /rpt_type=direct 
                     /rpt_unit_seq="atatgtccacgtttaccttgca" 
     repeat_region   247..268 
                     /function="control of DNA replication" 
                     /rpt_family="iteron" 
                     /rpt_type=direct 
                     /rpt_unit_seq="atatgtccacgtttaccttgca" 
     gene            322..1272 
                     /gene="repAci1" 
     CDS             322..1272 
                     /gene="repAci1" 
                     /note="replicase; plasmid replication protein" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="RepAci1" 
                     /protein_id="ACT98252.1" 
                     /db_xref="GI:254972055" 
                     
/translation="MRDLVVKDNALINASYNLDLVEQRLILLAIVEARESGKGINAND 
                     
PLEVHADSYINQFGVHRNTAYQALKDACKDLFARQFSYQEKKANGNIRNVMSRWVSQI 
                     
AYNDNEATVDLIFAPAVVPFITRLEEQFTKYELQQVSSLSSAYAIRLYELLIQWRSTG 
                     
KTPTIELQEFRKKLGVLDNEYLRMAHLKERVLELSIKQINEHTDITVKYEQHKRGRSI 
                     
SGFSFTFKQKKKDSPSIERDPNTLELFSKMTDAQRHMFANKLSELPEMGRYSQGTESY 
                     QQFAVRIAEMLQDPAQFKELYPYLKKVGYMPSNKKDTVNG" 
     gene            1265..1840 
                     /gene="repAci2" 
     CDS             1265..1840 
                     /gene="repAci2" 
                     /note="replicase; DNA replication protein" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="RepAci2" 
                     /protein_id="ACT98253.1" 
                     /db_xref="GI:254972056" 
                     
/translation="MAKLSLSEVSKKFHVDRSTIYRAVRNGRLSRSSDGQFDLAEVIR 
                     
CFGEPEQTSQKIESSKQEGDESTKKLIAHLENEVKKYQEREERLMQQIDRMQTLIELK 
                     
SVAPATAAPHQDATACDTKMPQHATTQQDTDNKKNNELNIAENVAVPQQETTAYHTQT 
                     LQHATLQSVAVPQHKKRGLFGRVLNAVFDND" 
     repeat_region   2850..3263 
                     /note="truncated due to the insertion of ISAba2" 
                     /allele="ISAba3" 
                     /mobile_element="insertion sequence:ISAba3" 
     CDS             complement(2883..>3263) 
                     /note="transposase; distrupted due to ISAba2 
insertion" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="truncated TnpA" 
                     /protein_id="ACT98254.1" 
                     /db_xref="GI:254972057" 
                     
/translation="KVDGKQNYQCKDCKRQFIGDHALSYLGCKSGITRKILQLMVRGS 
                     
GIRDIAEVERISIGKVLRTLTESTYEIQPQQSHYESLEVDEFWNFVGNKKNKQWLIFV 
                     QKSYFTSEKPDIFIGENIDTLNGF" 
     repeat_region   3264..4569 
                     /mobile_element="insertion sequence:ISAba2" 
     repeat_region   3264..3288 
                     /rpt_type=inverted 
     gene            3313..3630 
                     /gene="insA" 
     CDS             3313..3630 
                     /gene="insA" 
                     /note="transposase" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="insA" 
                     /protein_id="ACT98255.1" 
                     /db_xref="GI:254972058" 
                     
/translation="MTKPKYTPEIRDRAVQLLIESEKDYPSNWAAITAIAPKIGCTPE 
                     
TLRVWYLKHLDQQNPIKVQQASDQEKMKQMEREIKELKRANEILRKAAAFFAQAELDR 
                     PHK" 
     gene            3630..4532 
                     /gene="insB" 
     CDS             3630..4532 
                     /gene="insB" 
                     /note="transposase" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="insB" 
                     /protein_id="ACT98256.1" 
                     /db_xref="GI:254972059" 
                     
/translation="MVDFIHNNKDLYGVDAICRILPIAASTYYRTLDLADNPEHRAKR 
                     
DLHDLHHAEQIKRIWKESSGRYGVRKVWQKLKREGYIIARCTVARLMQKLGIQGVWRG 
                     
KNKQTTHSRDDQKRADDLVKRNFSADHPDQLWVADFTYIQTNSGWVYTAFIIDVFSRA 
                     
IVGWKVSTRMNTDMVLDALEQALHDRGMPKNVIHHSDRGVQYLSIRYTNRLEAANLRA 
                     
SVGTTGDSYDNALAETVNGLYKTEVIEYLKADWQGLADVQLATLNWVDWFNKERVHSA 
                     LGYVSPFDFEAMYYDKINPLGQVA" 
     repeat_region   4545..4569 
                     /rpt_type=inverted 
     CDS             complement(<4570..4640) 
                     /note="transposase" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="truncated TnpA" 
                     /protein_id="ACT98257.1" 
                     /db_xref="GI:254972060" 
                     /translation="MQITLAIKCPTCLSDSIKKNGIKV" 
     repeat_region   4570..4640 
                     /note="transposase; distrupted due to ISAba2 
insertion" 
                     /mobile_element="insertion sequence:ISAba3" 
     repeat_region   4677..4703 
                     /rpt_type=inverted 
     gene            4721..5563 
                     /gene="blaOXA-58" 
     CDS             4721..5563 
                     /gene="blaOXA-58" 
                     /note="carbapenem-hydrolyzing oxacillinase" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="OXA-58" 
                     /protein_id="ACT98258.1" 
                     /db_xref="GI:254972061" 
                     
/translation="MKLLKILSLVCLSISIGACAEHSMSRAKTSTIPQVNNSIIDQNV 
                     
QALFNEISADAVFVTYDGQNIKKYGTHLDRAKTAYIPASTFKIANALIGLENHKATST 
                     
EIFKWDGKPRFFKAWDKDFTLGEAMQASTVPVYQELARRIGPSLMQSELQRIGYGNMQ 
                     
IGTEVDQFWLKGPLTITPIQEVKFVYDLAQGQLPFKPEVQQQVKEMLYVERRGENRLY 
                     
AKSGWGMAVDPQVGWYVGFVEKADGQVVAFALNMQMKAGDDIALRKQLSLDVLDKLGV 
                     FHYL" 
     repeat_region   5574..>6073 
                     /mobile_element="insertion sequence:ISAba3" 
     repeat_region   5574..5600 
                     /rpt_type=inverted 
     CDS             5654..>6073 
                     /note="transposase" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="tnpA" 
                     /protein_id="ACT98259.1" 
                     /db_xref="GI:254972062" 
                     
/translation="MQITLAIKCPTCLSDSIKKNGIKVDGKQNYQCKDCKRQFIGDHA 
                     
LSYLGCKSGITRKILQLMVRGSGIRDIAEVERISIGKVLRTLTESTYEIQPQQSHYES 
                     LEVDEFWNFVGNKKNKQWLIYAYHRETGEIVAYVWGKR" 
ORIGIN       
        1 gtcacgccag tattaaccaa aaaattgccc caacgaactg agcgaaagcg aagttcaata 
       61 gagtttgagc gaagcgaaaa ccaagggcaa tttttcattc cctgggcttt taattatttt 
      121 aaagttttta aatactttta aatggcttga aagccttatg aataaagggt tttagctctt 
      181 atatgtccac gtttaccttg caatatgtcc acgtttacct tgcaatatgt ccacgtttac 
      241 cttgcaatat gtccacgttt accttgcatt agtacacaaa taatattaac gtgtacttat 
      301 acacaataaa aaatagtggc tatgagagat ttagttgtaa aggacaatgc cttaatcaac 
      361 gcaagctata acttagactt agtagaacaa cgtttaattt tattggctat tgttgaagca 
      421 agggaaagtg ggaaagggat taatgcaaat gatccattag aagttcatgc agatagttat 
      481 atcaatcaat ttggtgtaca ccgtaataca gcttatcaag ccttaaaaga tgcttgtaag 
      541 gatttattcg cgcgtcaatt tagctatcaa gagaaaaaag ctaatgggaa tatccgaaat 
      601 gttatgagtc gttgggtatc tcaaattgct tataacgaca atgaagcaac tgtagactta 
      661 atatttgcac ctgctgttgt tcccttcata acccgactgg aagaacaatt tactaaatat 
      721 gaattacagc aagttagtag tcttagtagc gcttatgcca ttcgcttata tgagcttcta 
      781 attcagtggc gaagcactgg taaaacccca accatagaac tacaagaatt tagaaagaag 
      841 ttaggcgttc ttgataatga atatttacgg atggctcatt taaaagagcg tgttttagag 
      901 ctttcaatta aacaaataaa tgagcatacg gatataactg taaaatatga acagcataaa 
      961 agaggacgtt ctatttcagg attttctttt acctttaaac agaagaagaa ggatagccca 
     1021 tcaatagaaa gagatccgaa cactttggag cttttttcaa agatgaccga tgctcaacgg 
     1081 catatgtttg caaataaact ttcagaactc cctgaaatgg gtcgctattc acaaggaaca 
     1141 gaaagctacc aacagtttgc tgtacgtatt gctgagatgc tacaagatcc cgctcaattc 
     1201 aaagagctat acccatacct aaaaaaagtg ggatacatgc catcaaataa aaaggacacc 
     1261 gtaaatggct aagttatcac taagtgaagt atctaaaaaa tttcatgtgg atagatcaac 
     1321 catttacaga gctgtacgta atggacgttt atcacgctcc agtgatggac aattcgatct 
     1381 agcagaggtc atacgatgct ttggagaacc tgagcaaaca tctcaaaaaa ttgaatcatc 
     1441 taagcaagaa ggtgatgaat ctacaaaaaa acttattgcc catttagaaa atgaagtcaa 
     1501 aaaataccaa gaacgtgaag aacggttaat gcaacaaatt gaccgtatgc aaacactcat 
     1561 tgagctgaaa agtgttgcac ctgccacagc agcaccacac caagatgcta cggcatgcga 
     1621 caccaagatg ccacagcatg cgacaacaca acaagacact gataacaaaa agaataatga 
     1681 attaaatatt gcagaaaatg tagcagtgcc acagcaagaa actacggcat accacaccca 
     1741 aacgctacag catgccacgt tgcaaagtgt ggcagtgcca caacacaaaa aacgtggttt 
     1801 atttggccgt gtgctgaatg ccgtctttga taatgactga gcaataaggg tgaaagatca 
     1861 tgccgaaact gaaagacatt gccctgggaa ttattgtagc tccgctgctg atcccgatca 
     1921 tgctgattgc atcgtaccag gataaaaagg cgctgaagaa agagctggat gaatgccaaa 
     1981 aagaaaaaga ccaggcatcc tgattattca attgagctaa tcaaaagtgt ggaacattga 
     2041 tgaaataata gcgtggaacg tgaaaagtca taaaaaaagc ccgaacaggg atgctcgggc 
     2101 tataaactag aaactacagc gttgaattat aaggataatt atacagcatt tcgtataagg 
     2161 tgtattatgt taattttagg aaatattaaa actaattttc agacttatcc caccaacttt 
     2221 gagctaaatc agtattttta ggaataccta taccatcacg atacataacg gaaagacttc 
     2281 gcattgcttt cttattacct aactttgcag ccttttcacg aagttcaaaa gctttattaa 
     2341 tattaacttc tattccgcta tctgcacgag tatatagatc agctaactca accattgatt 
     2401 cagaatggcc attttctgag gctttctgaa accacttaaa agctttttgg aaatgttcta 
     2461 aagaatcgtt tttgtcatca tcttccatta atctagcata agtaacatat ccatcagcta 
     2521 accaaaacat tgctgctaca tttccatttt ctgctgattt aagagcccaa acttcagctt 
     2581 gattttcatc tgaatcaaca ccatgaccat atagataaat ctcggctaat tctaactgag 
     2641 cagaagtatc tccattttct gctttcgcta ataaatcatt agaaaaaaca ggttctgcaa 
     2701 atgtttccat tgaaaggcaa actcctaaag ccataaaaat atttgttaat ttattcaatt 
     2761 tttaaccttt aaactaaact gttaggcttg tatattttta tatcatacct aaaagaaaac 
     2821 tctaaaatta gagtatgtct tatctctatt taacataatg gctgttatac gaaacgagag 
     2881 tgttagaacc catttaaagt gtctatattc tcaccaataa aaatgtccgg tttctccgag 
     2941 gtaaaatatg acttttgaac aaaaataagc cattgtttat tctttttatt tccaacaaaa 
     3001 ttccagaact catctacttc gagagattca taatgacttt gctgaggctg aatttcatag 
     3061 gttgattcag ttaaagtacg taaaacttta ccgatactga tgcgctcaac ttcagcaata 
     3121 tctcgtatac cgctgcctct gaccatcaac tgtaatattt tacgagtaat acctgactta 
     3181 catcctagat agctcagtgc atgatcacca ataaactgac gtttacagtc tttgcactga 
     3241 tagttttgtt tcccatctac tttgaaccgt accgggtttg tcggagacca actttcttga 
     3301 gagaatgtcc cgatgacaaa accaaaatat acccctgaaa tccgagatag agcggttcaa 
     3361 ttattgattg aatccgaaaa agattatcca tcgaattggg ctgcaatcac tgctattgct 
     3421 cccaagatag gttgtactcc tgaaacactg cgtgtttggt atttaaaaca tctcgatcaa 
     3481 caaaatccta tcaaagtaca acaggcatca gatcaagaaa aaatgaagca gatggaacgt 
     3541 gaaatcaaag aattaaagcg tgccaatgaa attctacgta aagcagctgc ttttttcgcc 
     3601 caggcggagc tcgaccgccc acacaaataa tggtggattt catccataac aataaagact 
     3661 tatatggtgt tgatgcgatt tgtaggattt taccgatcgc agcttcaacc tattaccgaa 
     3721 ctttagatct cgcggacaat ccagaacatc gagcgaagcg agatttacat gacttgcatc 
     3781 atgctgaaca aattaaacga atttggaagg aaagttcagg tcgatatggt gtacgtaaag 
     3841 tttggcaaaa actgaaacgt gaaggctata ttattgcacg ctgtacagtt gctcgattga 
     3901 tgcaaaagct aggtatacaa ggtgtttggc gaggtaagaa taaacaaact acccatagcc 
     3961 gagatgatca aaaacgagca gatgacttgg tgaaacgcaa ttttagtgct gatcaccctg 
     4021 accagctgtg ggtcgctgac tttacgtata ttcaaacaaa ttcaggctgg gtctataccg 
     4081 cctttattat tgatgtgttc tcgcgagcaa ttgttggatg gaaagtatca acacggatga 
     4141 atacagacat ggtgctcgat gcactggagc aagcattgca tgatcgaggc atgccaaaga 
     4201 acgtgattca tcatagtgac agaggtgtgc aatatctttc cattcgttat accaatcgtt 
     4261 tagaagcagc aaatttacga gcatcagtcg gtacgaccgg tgattcatac gataatgctt 
     4321 tggctgaaac ggtgaatggc ttatacaaaa cagaggtgat tgaatattta aaagcggatt 
     4381 ggcaaggttt agcggatgta caacttgcga cattaaattg ggtagattgg ttcaataaag 
     4441 agcgtgtaca tagtgcacta ggttatgtgt caccttttga ttttgaagca atgtactatg 
     4501 ataaaattaa cccgttaggt caggtggcct aacttaaata aaaagtctcc gacaaacccg 
     4561 gtacggttca ctttgatacc atttttcttt atactatcac tgaggcaggt tggacatttg 
     4621 attgctagag ttatttgcat ttctctattt tatcaaaatc caatcggctt tttcttcagc 
     4681 atactttttg aaacactacc aaattttaaa gttgtatatc atgaaattat taaaaatatt 
     4741 gagtttagtt tgcttaagca taagtattgg ggcttgtgct gagcatagta tgagtcgagc 
     4801 aaaaacaagt acaattccac aagtgaataa ctcaatcatc gatcagaatg ttcaagcgct 
     4861 ttttaatgaa atctcagctg atgctgtgtt tgtcacatat gatggtcaaa atattaaaaa 
     4921 atatggcacg catttagacc gagcaaaaac agcttatatt cctgcatcta catttaaaat 
     4981 tgccaatgca ctaattggtt tagaaaatca taaagcaaca tctacagaaa tatttaagtg 
     5041 ggatggaaag ccacgttttt ttaaagcatg ggacaaagat tttactttgg gcgaagccat 
     5101 gcaagcatct acagtgcctg tatatcaaga attggcacgt cgtattggtc caagcttaat 
     5161 gcaaagtgaa ttgcaacgta ttggttatgg caatatgcaa ataggcacgg aagttgatca 
     5221 attttggttg aaagggcctt tgacaattac acctatacaa gaagtaaagt ttgtgtatga 
     5281 tttagcccaa gggcaattgc cttttaaacc tgaagttcag caacaagtga aagagatgtt 
     5341 gtatgtagag cgcagagggg agaatcgtct atatgctaaa agtggctggg gaatggctgt 
     5401 agacccgcaa gtgggttggt atgtgggttt tgttgaaaag gcagatgggc aagtggtggc 
     5461 atttgcttta aatatgcaaa tgaaagctgg tgatgatatt gctctacgta aacaattgtc 
     5521 tttagatgtg ctagataagt tgggtgtttt tcattattta taagaattag aagtttgagg 
     5581 ttaatctatt tttggtagtg tttcaaaaag tatgctgaag aaaaagccga ttggattttg 
     5641 ataaaataga gaaatgcaaa taactctagc aatcaaatgt ccaacctgcc tcagtgatag 
     5701 tataaagaaa aatggtatca aagtagatgg gaaacaaaac tatcagtgca aagactgtaa 
     5761 acgtcagttt attggtgatc atgcactgag ctatctagga tgtaagtcag gtattactcg 
     5821 taaaatatta cagttgatgg tcagaggcag cggtatacga gatattgctg aagttgagcg 
     5881 catcagtatc ggtaaagttt tacgtacttt aactgaatca acctatgaaa ttcagcctca 
     5941 gcaaagtcat tatgaatctc tcgaagtaga tgagttctgg aattttgttg gaaataaaaa 
     6001 gaataaacaa tggcttattt acgcctatca tcgagaaaca ggtgaaattg ttgcttatgt 
     6061 ttggggtaaa cga 
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